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Quality Assurance of Advanced Treatment Modalities Using PRESAGE® Dosimeters

Ryan G. Lafratta, M.S.
Advisory Professor: Geoffrey Ibbott, Ph.D.

Computer-controlled therapy machines allow for increasingly complex plans, as there are
more variables that can be tuned to produce the ideal result. This makes it increasingly difficult to
assure the intended calculated dose is being delivered correctly using current techniques that are 2Dbased because the resultant dose distributions can differ markedly in various sections of the target. A
measurement of composite dose from the entire plan should be included in patient-specific IMRT
QA. A volumetric dosimeter such as PRESAGE® is able to provide a complete 3D measured
dosimetry dataset with one treatment plan delivery. It was hypothesized that a PRESAGE® dosimeter
would agree with 2D measurements within ±5%/3mm using a gamma index analysis. The
PRESAGE® dosimeter will detect dose discrepancies not detected with 2D measurements resulting
in a 5% change in the normal tissue complication probability (NTCP). An optical CT scanner was
tested for reproducibility and reliability and a standard operating procedure was created. The
PRESAGE® dosimeters were extensively tested for dose stability over a range of time for remote
dosimetry applications. The effect of temperature changes before, during and after irradiation was
investigated. The dosimeter was found to be appropriate for remote dosimetry for relative dose
measurements. The IROC-Houston Head and Neck (HN) phantom was imaged with an x-ray CT
scanner. One scan used an insert for film and thermoluminescent dosimeter (TLD). A second scan
was taken using a PRESAGE® insert. An IMRT treatment plan was created and delivered to the
phantom using each insert. The gamma index analysis was performed at ±5%/3mm. The PRESAGE®
measurements agreed well with the 2D measurements. Various gamma constraints were applied to
the measured data to determine an appropriate passing criterion for 3D gamma analysis. The IMRT
treatment plan was modified to induce several different types of treatment and delivery errors. The

vi
plans were analyzed using 2D and 3D gamma analysis. Two plans passed a 2D metric while failing
the 3D metric with one of the plans also having a 5% change in NTCP. The hypothesis was proven
correct and further work should be considered to bring PRESAGE® into a phantom dosimetry
program.
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1
1.1

Chapter 1 - Introduction

Significance
Modern therapy machines are mechanically precise and computer-controlled, allowing for

dynamic deliveries that can include varying dose rates, beam apertures, collimator orientations,
gantry angles and couch positions in a continuous fashion. A treatment plan that utilizes these tools
is volumetric in design and usually has significant dose gradients. Dose verification of these complex
treatments is becoming increasingly important in the clinic as computer errors in delivery can occur
and treatment planning systems (TPS) might not be fully commissioned to accurately calculate every
possible variable available in delivery. Since these dose distributions normally are designed to
conform to irregularly shaped targets, traditional dosimetry methods including ion chamber and
planar film measurements become increasingly time consuming and may not be sufficiently
comprehensive to verify correct delivery (1).

The dose distributions for Intensity Modulated

Radiation Therapy (IMRT) require quality assurance (QA) checks of the cumulative dose delivered
and not just the an individual segment of delivery (2). Many QA programs for IMRT focus on ion
chamber measurements with planar dosimetry. The gamma function (3) is widely used to compare a
measured planar dose distribution to the distribution calculated by the TPS. Studies have shown this
method of single planar dosimetry can produce gamma analysis results that are insensitive to the
changes in measured and calculated IMRT dose distributions (4, 5). These studies suggest that a
measurement of composite dose from the entire plan be included in patient-specific IMRT QA. A
volumetric dosimeter such as PRESAGE® is able to provide a complete 3D measured dosimetry
dataset with one treatment plan delivery.
The Imaging and Radiation Oncology Core Houston Quality Assurance Center (IROCHouston) uses anthropomorphic phantoms as an end-to-end test for quality assurance at institutions
participating in clinical trials. The phantoms are able to test imaging, treatment planning, patient
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setup and treatment delivery. At this time, the phantoms use thermoluminescent dosimeters (TLD)
and radiochromic film to measure dose and dose distributions, respectively. This design yields only
two or three planes of dose information, depending on the phantom, to compare to the treatment plan
calculated data. From data compiled in 2008, almost 30% of institutions failed to deliver dose
distributions, using the IMRT Head and Neck (HN) phantom, that agreed with their treatment plans
within the constraints of 7%/4 mm (6). Having a full 3D dose distribution could help decipher the
type of error (positioning, MLC malfunction etc.) that could have occurred during the process and
help IROC-Houston with appropriate QA recommendations for the institution.
The overall clinical value of 3D dosimetry has not been widely tested. Difficulty in
maintaining consistent formulations for these dosimeters, complicated equipment for fabrication,
expensive and time-consuming readout systems, and the learning curve for the person conducting the
measurements have factored into the slow uptake in the clinic. While several groups have been able
to use 3D dosimeters for clinical purposes there have been no investigations into the ability of
volumetric data to significantly impact clinical practices (7-9). For example, it is not known whether
easily attainable volumetric data could affect clinical practices for patient quality assurance. Are we
able to estimate changes in patient outcome based on the difference in the calculated and delivered
dose distribution? Would the plan then be considered clinically unacceptable after measured QA and
re-planned? A criterion would have to be established to designate a threshold at which treatment
would be postponed due to volumetric data results for further inquiry.
Another use would be the remote dosimetry aspect for 3D phantoms. As mentioned earlier,
almost 30% of institutions from 2008 and before did not pass the credentialing test with the head and
neck IMRT phantom. A volumetric dataset might capture even more errors, might be able to
determine the source of the error, or might capture a lower percentage of data points exceeding a 2-D
QA Pass Criteria that would allow False Positive in QA.
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With routine radiation therapy treatments becoming more advanced, QA protocols need to
keep pace for physicists to ensure the safe and reliable delivery of the intended treatment. 3D
dosimeters have matured to the point that common clinical use could be feasible. Research into
situations where a measured 3D dataset would be of greater value than the current process of 2D
dosimetry is necessary.

1.2

PRESAGE® Dosimeters
In 1950, Day and Stein (10) introduced the idea to use radiosensitive gels to measure

radiation. The modern use of gels for radiation dosimetry resulted from work done by Gore in 1984
(11). Since then, work has focused on two types of gel dosimeters, containing either ferrous sulphate
or a polymer.
Most work initially involved the use of Fricke dosimeters (Fe(SO4)) blended in waterequivalent gels. Gore et al demonstrated that magnetic resonance images (MRI) indicate the
concentration of Fe3+ produced, which is related directly to absorbed radiation dose (11). Gore’s
work to combine a chemical dosimeter, gelling agent, and imaging readout yielded the first truly 3D
dosimeter for radiotherapy. However, the general use of the initial dosimeter was hindered by
difficulties in making the gel dosimeter and the rapid diffusion of the ions in the medium. Variations
of composition were tested but diffusion remained a problem for this type of gel dosimeter(12). In
addition, access to an MRI machine in most hospitals is limited and expensive. Optical computed
tomography (OCT) systems were tested as an alternative readout method but the results were not
compelling as compared to MRI since these dosimeters lessened light attenuation mainly by
scattering and not absorption.
The next generation of gel dosimeters involved the use of polymers (notably
polyacrylamide) rather than ferrous sulfate. These dosimeters were also read out using MRI.
However, these dosimeters were sensitive to oxygen because it scavenges free radical initiators of
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the polymerization reaction. Many variations of polymer gel dosimeters were investigated (12-14)but
this type of gel dosimeter has experienced only limited clinical acceptance because of the complex
manufacturing process required to eliminate oxygen from the gel system as well as the difficulty in
containing the gels in some sort of anthropomorphic phantom or shape. Again, the need for MRI
readout was a hindrance and OCT readout suffered from the same inadequacies as for the Ferrous
Sulfate gels.
In 2003, a new dosimeter named PRESAGE® [Heuris Pharma, LLC, Skillman, NJ] was
introduced (15) and was more fully characterized in

2006 (16). This dosimeter is a solid

polyurethane dosimeter with a leuco-dye, o-MeO-LMG, synthesized by Heuris Pharma. Free radical
initiators change the leuco malachite green to malachite green causing a change in color and
therefore optical density after exposure to ionizing radiation. Quantifying the change in optical
density leads to the determination of radiation dose distribution.

Figure 1-1: bis-(4-dimethylamino-phenyl)-(2-methoxy-phenyl)-methane (o-MeO-LMG)

This dosimeter has several advantages over gel dosimetry including its insensitivity to
oxygen contamination, stable optical absorption for wide dose range and a solid state that can be
machined to any shape and does not require an outer container (16). Certain gels can often have a
diffusion problem that is not seen in PRESAGE® (17). PRESAGE® is light absorbing rather than light
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scattering allowing it to be read using an optical CT technique (16). Studies have been conducted to
show at ~633 nm (the red wavelength) there is a maximum change in the radiation induced optical
density (18).

Several studies have been performed investigating the use of PRESAGE®. The linearity of
the dose response at low energies has been confirmed by several sources (16, 19). A post-irradiation
stability using has been marked at 5 days by Guo et al. (18). Skyt et al. determined that temperature
effects on PRESAGE® has an effect on dose response (20). These studies were all conducted with
cuvettes with large volume measurements were either assumed to hold true or are pending future
research.
An optical CT of the PRESAGE® dosimeter is performed to capture the volumetric dataset.
The principles are described in the next section.

1.3
1.3.1

Optical CT
Principles of Optical CT
Beer’s Law describes how light and X-rays are attenuated through a medium. By using the

linear attenuation coefficient, μ, of the medium the intensity of light measured at distance s along the
ray path is given by
𝑰𝑰 = 𝑰𝑰𝟎𝟎 𝒆𝒆𝒆𝒆𝒆𝒆 �− �

.

𝒓𝒓𝒓𝒓𝒓𝒓 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑

𝝁𝝁(𝒔𝒔) 𝒅𝒅𝒅𝒅�

Equation 1-1

where I0 is the light intensity without the sample in the path of the light. Obtaining the projections at
different rotation angles creates a sinogram in Radon space. The optical attenuation of the sample
can then be found using filtered back-projection as in x-ray CT (21). Note that the intensity I is
related to optical density as OD=-log10(I/I0)/sample length. Typically, the optical density of a
dosimeter such as film is taken as a whole and the OD is dimensionless. However, with 3D
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dosimeters OD has units of cm-1 as OD is an intensive property of the sample that is imaged within
each voxel.
In broad beam optical CT, such as we use with PRESAGE®, a uniform light source is
measured with a charge-coupled device (CCD) camera. At each projection angle on a PRESAGE®
phantom, the Radon Transform (RT) is used to create a 2D plane of data providing a row of the
sinogram in RT space for every slice of the dosimeter at one time. Summing projections at multiple
angles creates a full sinogram that can be deconvolved into a true 3D reconstruction.
1.3.2

Duke Midsized Optical-CT System for the IROC-Houston (DMOS-IROC)
Rather than a Point Source of light, for PRESAGE® readout we use a broad beam optical CT

system designed by Duke University (22). It consists of a fixed, uniform line light source measured
by a charge-coupled device (CCD) camera. The dosimeter is placed in a water bath on a rotating
pedestal and the captured data at each angle is combined to create the 3D data set.
The system came with operating instructions addressing how to image and reconstruct a
dosimeter but the procedures did not detail which settings to input therefore it was necessary to
create a set of uniform procedures for collecting raw data and its subsequent analysis for our
purposes. Image capture is run in LabVIEW [National Instruments, Austin, TX] while reconstruction
is completed with MATLAB® [MathWorks, Natick, MA]. The final reconstruction is saved in a file
intended for use with CERR (The Computational Environment for Radiotherapy Research), a
MATLAB-based program that can compare dose distributions created in many planning systems.

1.4

IMRT Quality Assurance and IROC-Houston Phantoms
The dose distributions for Intensity Modulated Radiation Therapy (IMRT) require quality

assurance checks of the cumulative dose delivered and not just the an individual segment of delivery
(2). Many QA programs for IMRT focus on ion chamber measurements with planar dosimetry. The
gamma function (3) is widely used to compare a measured planar dose distribution to the distribution
to the distribution calculated by the TPS. Studies have shown this method of single planar dosimetry
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can produce gamma analysis results that are insensitive to the changes in measured and calculated
IMRT dose distributions (4, 5). These studies suggest that a measurement of composite dose from
the entire plan be included in patient-specific IMRT QA. A composite plan is tested by IROCHouston and will be used in this study.

1.4.1

Film and TLD Dosimetry
The phantom used in this project uses film and TLD to measure dose. The phantom is fitted

for double-loaded capsules of LiF TLD 100 powder. In thermoluminescent (TL) detectors, incident
radiation releases electrons from the valence band to the conduction band and the electrons are then
captured by various trapping centers (23). When exposed to heat, these trapped electrons are then
able to return to the conduction band while releasing light. A photomultiplier tube (PMT) records the
amount of light and a glow curve is produced comparing the light signal to the temperature at the
time of emission. The area under the glow curve corresponds to the number of photons released.
Using this signal (T), along with correction factors for energy (Ke), linearity (Kl), fading (Kf) and
system sensitivity (S) the dose can be calculated using Equation 1-2.

D = T × Ke × Kl × K f × S

Equation 1-2

EBT2 Gafchromic film (ISP, Wayne, NJ) is a self-developing yellow film commonly used in
IMRT QA comprised of an active layer laminated by two polyester layers with an absorbance
spectrum near 636 nm (24). The dose has been found to stabilize by 24 hours post-irradiation and
can be digitized with both flatbed scanners and film densitometers.
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1.5

Gamma Analysis
There are many ways to compare two dose distributions. A dose difference test compares the

dose difference in distributions point by point is overly sensitive in a steep dose gradient since small
offsets in dose distribution are shown as large dose difference in the steep dose gradients (3). The
distance to agreement test was developed to overcome this sensitivity by independently searching
each point of one dose distribution to locate the nearest identical dose value in the second dose
distribution (25). This test had the opposite sensitivity issues by magnifying differences in the
shallow dose gradient. Low et al. developed the gamma analysis tool combining dose and spatial
information in a single test to offset the sensitivities of using the tests separately (26). The dose
distributions are re-normalized in a space with dose and spatial coordinates where the axis are the
acceptance criteria and the center is the reference point from one dose distribution. The minimum
distance from the reference point to the measured point of the second distribution is the gamma
index.
Literature has shown volumetric datasets could increase the passing rate of a gamma analysis
while others have found the opposite result when comparing different dosimeter types as was done in
this study (27, 28).

1.6

Normal Tissue Complication Probability (NTCP)
Treatment plans are assessed by their ability to control the tumor while sparing normal tissue

in surrounding sites. The NTCP is a model that helps estimate the risk of complication to an organ or
tissue based on the dose delivered to a volume. The most widely used NTCP model is the LymanKutcher-Burman (LKB) model (29). This model combines the Lyman NTCP model (30) with the
Kutcher and Burman DVH modification for partial organ irradiation (31).
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Equations 1-2 and 1-3 describe the LKB model that is a function of dose (D) and volume (v). D50(v)
is the 50% tolerance dose for uniform partial-organ irradiation to the volume v (32) and is described
by equation 1-4. The variables m and a are found by fitting tolerance doses: m characterizes the slope
of the dose response-function and a characterizes the volume effect.
𝑫𝑫𝟓𝟓𝟓𝟓 (𝒗𝒗) = 𝑫𝑫𝟓𝟓𝟓𝟓 (𝟏𝟏) ∙ 𝒗𝒗−𝟏𝟏⁄𝒂𝒂

𝑬𝑬𝑬𝑬𝑬𝑬 =

�� 𝒗𝒗𝒊𝒊 𝑫𝑫𝒂𝒂𝒊𝒊 �

𝟏𝟏�
𝒂𝒂

Equation 1-5
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The equivalent uniform dose (EUD) shown in equation 1-5 was introduced by Niemierko (33) and is
used by CERR to evaluate the NTCP by replacing the total dose D in equation 1-4 with EUD (34).
By registering the PRESAGE® dose distribution to the treatment plan using CERR, the NTCP can be
calculated for both measured and calculated dose distributions using the plan’s organ contours to
obtain volume (28). This allows for a quantifiable metric for change in tumor control should the dose
distributions differ.

1.7

Hypothesis and Specific Aims
The hypothesis for this project is that dose distributions for complex dose distributions

measured with the PRESAGE® 3D dosimeter will agree with 2D measurements to within ±5%/3mm
using a gamma index analysis. The PRESAGE® dosimeter will detect dose distribution discrepancies
for complex treatments not detected by 2D planar measurements that will result in a 5% difference in
NTCP. This was tested with four specific aims.
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1.7.1

Specific Aim 1: Determine a standardized protocol for reading dosimeters and performing
data analysis
This aim verifies the alignment of the optical CT scanner used to image the dosimeters and

creates a quality assurance protocol to verify the uniformity and constancy of optical density prior to
data acquisition. A standard operating procedure was created to ensure optical scanning would be
reproducible independent of the user.
1.7.2

Specific Aim 2: Assess the capability of PRESAGE® dosimeters for remote quality
assurance
A “standard” calibration scheme was developed. Age dependence of the dosimeter was

assessed and the influence (if any) of the readout procedure on the dosimeter was quantified. Effects
of shipping to offsite facilities were evaluated to determine if phantom studies could be conducted
remotely.
1.7.3

Specific Aim 3: Examine the use of the system as a clinical quality assurance tool in
radiation therapy
Treatment plans were created starting with open fields and moving towards complex,

clinically relevant plans. Data from irradiated dosimeters was compared against a standard 2D
measurement quality assurance test and the computed plan from the treatment planning system
(TPS). Gamma index analyses at different constraints were applied for comparison.
1.7.4

Specific Aim 4: Demonstrate the benefits to the clinic from a measured 3D dataset
Using NTCP models, the complication probability was calculated from the 3D dose

distributions from the TPS calculation and from the PRESAGE® measurements.
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2 Chapter 2 – Specific Aim 1

2.1

Rationale
The first specific aim is to determine a standardized protocol for reading dosimeters and

performing data analysis. This aim is intended to prepare and optimize the Duke Midsized Optical
CT Scanner for the IROC-Houston (DMOS-IROC) [Duke University, Durham, NC] for use as a
routine quality assurance tool in the remote phantom program.
Duke University has been working on optical CT scanners for 3D dosimetry and
PRESAGE® for several years (35, 36). The DMOS-IROC was built at Duke University specifically
for the IROC-Houston’s use. The scanner uses a 633 nm light source since this is the optical
absorption wavelength for PRESAGE®. A photograph of the scanner is shown in Figure 2-1. The
light source passes through a diffuser (to create a uniform field) and a band pass filter leaving the
first of a matched set of telecentric lenses before entering a tank filled with a mixture of octyl
salicylate, ocytl cinnamate and mineral oil to match the refractive index of the dosimeter and
minimize the refraction and reflection of incident light on the dosimeter. The dosimeter sits on a
rotating stage and as the dosimeter rotates the light then enters the second telecentric lens and is
captured by a CCD camera.
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Figure 2-1: The DMOS-IROC with the CCD camera on the left and the light source shining from the
right.

Initial commissioning tests were performed at Duke University before installation at IROC-Houston
(37) and these commissioning tests were repeated for verification in a separate study.
No quality assurance protocol was suggested for the scanner at installation so one needed to
be developed to confirm whether any measured dose difference was due to irradiation and not
improper imaging. Discrepancies in dose distributions can be difficult to discern in anthropomorphic
phantoms and variables should be contained when possible. Procedures for QA on the scanner and
standardization of use across several users need to be established prior to performing patient QA.
The first specific aim was separated into four separate sections:
•

Setting the physical light source

•

Setting the camera’s field of view and the center of rotation for reconstruction

•

Creating a quality control program

•

Finding the optimal number of averaged images for each projection angle
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2.2
2.2.1

Methods
Light Source Physical Setting

One of the most important settings for the DMOS-IROC is the light source. The main objective is to
set the LED light source to create a uniform flood field with as much light as possible passing
through the system. Equation 2-1 describes how the dose is measured where
pre-scan camera reading in the center of the dosimeter,

is the un-irradiated

is the desired minimum camera

reading, s is the sensitivity (ΔOD/Gy/cm) and x is the irradiated path length through the dosimeter.
The change in OD is log(Ipre/Iirradiated)/x. As previously stated in Section1.3.1, with 3D dosimeters OD
has units of cm-1 or mm-1 as OD is an intensive property of the sample that is imaged within each
voxel. The amount of light through the system partly determines the dynamic range that can be
achieved. The amount of light that exits the dosimeter decreases as the light input from the source
decreases. When too little light is transmitted to the camera the dose that can be delivered to the
dosimeter is limited.

 I pre
log
 I irradiated
Dose =
s⋅x





Equation 2-1

An uneven flood field limits the usable Field of View (FOV) for dosimeters. With varying
phantom sizes in the IROC-Houston phantom program, a maximized uniform flood field is
necessary.
To find an optimal setting, the light source was moved towards and away from the lens as
well as rotated. Band pass filters and diffusers were interchanged until the most uniform field could
be created. The light source was then affixed to the system and not changed.
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2.2.2

Camera Field of View
The camera FOV can be sized to only show the dosimeter rather than capturing an image of

the majority of the tank. The area of the FOV corresponds to the image size that must be stored and
the time needed for reconstruction. Using the smallest FOV possible saves valuable disk space and
shortens the reconstruction. As the FOV changed, the center of rotation for the filtered back
projection also changed. The center of rotation for each FOV needed to be defined for proper
reconstruction.
To image a dosimeter first the dosimeter is placed in the tank. The fluid is matched to the
dosimeter by changing the concentration levels of the fluid until optical edge artifacts are removed as
shown in Figure 2-2.
Fluid too high

Indexed matched

Figure 2-2: Example of minimizing edge artifacts by matching the refractive index fluid

The captured image data is run in LabVIEW and reconstruction is completed with
MATLAB®. The rotation angle and number of projections is input into the acquisition software. The
flood image was acquired without the dosimeter in the aquarium and was be a single projection with
200 images averaged. The dark image was taken in the same manner but with the light physically
blocked from reaching the camera. The flood and dark images were taken for each dosimeter. The
sinogram was created using the flood and dark field corrected projection images. The pre-irradiation
sinogram and post-irradiation sinogram were subtracted to produce a sinogram that was comprised
entirely of change in optical density. At this point, the reconstruction width of each voxel was
selected. The subtracted sinogram was created and then reconstructed into a 3D cube of data by
filtered back projection with a user defined filter and center of rotation. This cube was exported into
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the CERR environment for further evaluation that could include CT-dose profiles and dose
calculations in the area of interest.
A FOV was chosen for each size dosimeter. A cylindrical dosimeter that fits in the FOV was
irradiated with a single 4 cm by 4 cm dose field that fits completely within the dosimeter. During
reconstruction, the user was asked to select the center of rotation. The center was moved until the
reconstruction was done correctly and was recorded. This was qualitatively decided when the outer
edge of the dosimeter is a single circle and the edge of the square field is sharp. The center of
rotation was found for different size FOVs for consistency and reproducibility as new sizes of
dosimeters are ordered. A list of commonly ordered dosimeter sizes was created along with the
appropriate center of rotation. While this experiment focused on the dosimeters used for this project,
the list was continually updated as different dosimeters were created for other experiments using the
DMOS-IROC. A spreadsheet with the center of rotations was saved to the Desktop of the DMOSIROC computer for easy access for all users of the system.
2.2.3

DMOS-IROC Quality Control
To use 3D dosimetry as a part of an official remote dosimetry service, quality control on the

IROC-Houston side also needs to be implemented. Monthly quality assurance should be done to
verify the stability of the light source and camera as a system.
Three separate checks of the system’s function are tested at least on a monthly schedule.
First, the flood field is checked to ensure the raw counts without a dosimeter are still hovering near
3500 raw counts with the camera shutter set at 150 to compare to installation flood field. As major
changes occur, the “baseline” flood can be reassigned. Major changes include realignment, new
lenses, new diffusers and color changes in the fluid. Figure 2-3 shows examples of changing
“baseline” flood fields over scanner upgrades (top row) and an example of subsequent flood fields
captured for monthly stability check (bottom row)
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Figure 2-3: Flood Fields over Time

The second check of the system is the motor start position and the physical step size
compared to the software’s command. The start position of the motor can be reset accidently if the
applications are not closed properly at the end of a scan or if aborted incorrectly in the middle of a
scan. Checking the start position ensures the pre and post scans are aligned correctly. Physical hash
marks on the motor were checked for alignment when the motor was sent to 0 degrees. The motor
(Figure 2-4) was then told to move 5 and 10 degrees and the hash marks were recorded.

Figure 2-4: DMOS-IROC Motor

The third check of the system is the tank check. Seals are checked for fluid leakage around
the glass and at the base. Filter tubes are checked for cracking and aging.
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2.2.4

Projection images
The use of the DMOS-IROC was outlined in Section 2.2.2. A flowchart shown in Figure 2-5

describes the user inputs for image acquisition (DMOS-IROC settings) and reconstruction.

Figure 2-5: Flow Chart showing the settings for image acquisition and reconstruction

The number of degrees per rotation and the number of projection images determined the minimum
voxel edge length for the reconstructed image. The flood and dark image average number of images
is set to 200 for all irradiations. This was the maximum number of images that could be captured.
The center of rotation for the reconstruction was determined using the methodology described in
Section 2.2.2. The final user input determined was the number of projection images averaged
together for each degree of rotation. This was the time limiting portion of scanning.
A dosimeter was placed in the tank and images averaged input was set to the default setting
of 25. This setting takes 25 projection images and averages them together as one projection. The
signal to noise ratio increases with increasing projections to average. The scan time also increases
with increasing images averaged. This number was lowered in increments of 5 until 10 images had
been reached. Then the number of averages was decreased in increments of 1 until 7 images had
been reached. The original reconstruction (with 25 images averaged) was used as a baseline until a
noticeable difference was recorded. The minimum projection average was used for all other image
acquisitions.
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2.3
2.3.1

Results
Light Source Physical Setting
The lens was set to allow as uniform a flood field as possible. The DMOS-IROC has brighter

outer edges as compared to the center. With the maximum field of view, the center flood image had a
raw count of 3500. Using the FOV for the HN phantom the flooded out region (=4500) was
minimized to the outer corners and outside the field of the dosimeter.
2.3.2

Camera Field of View
Figure 2-6 shows an example of changing the center of rotation value. On the left is an

incorrect value of 295 while on the right is a correct value of 316.

Figure 2-6: Center of Rotation with incorrect (left) and correct (right) values

Table 2-1 lists the camera FOV options and matching center of rotation (COR) values.
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Dosimeter
Small Standard (Prior to
12/2011)
Large Standard (Prior to 12/2011)
1 kg HN Insert
Spine Insert
7cm x 9cm Nominal Dosimeter
Cyberknife Standard
Breast Phantom

Left
120

Top
150

Width
600

Height
454

COR
291

100
160
250
250
320
89

110
30
40
280
194
0

605
1170
1000
1000
800
1303

461
1000
960
760
846
1040

316
585
520
515
430
660

Table 2-1: Center of Rotation Settings

The two bolded values were used in this study. Note the change after December 2011 when the
system’s camera was upgraded and therefore new values had to be quantified. Other dosimeters used
in separate experiments are also listed demonstrating the range of customization for the DMOSIROC.
2.3.3

DMOS Quality Control
A chart of the flood field over the course of experiments in this project is shown in Figure

2-7. Gaps in information are due to the system being down for maintenance, upgrades or not in use
at that time. The dark field has not changed in any measurable way. After August of 2013, the 3D
dose lab group began varying formulations of PRESAGE®, all with separate refractive indexes.
From this point on the flood field could change on a scan by scan basis and monthly flood field
checks were discontinued.
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Figure 2-7: Flood Field Center Value over time

The motor was out of its start position 8 times since February 2011 when it was added to the
QA check. All 7 were accounted for as times when LabView either crashed mid-scan or was shut
down improperly. LabView crashes when settings are selected out of order but users have been
trained to reset the motor after a crash and to verify the motor’s start position prior to any scanning.

Hose
Integrity

Leaks

Motor
Position

Flood
Field

Lens
Offset

Date /
initials

Month
Table 2-2: Example of monthly checklist posted in scanning workroom to be initialed by user
performing QC

A checklist (Table 2-2) was posted in the scanning workroom to perform daily checks and to
sign off on monthly checks. Monthly, the seals are checked for leaking fluid, the filter tubes are
checked for leakage near the tank and filter and for physical degradation by the filter pump. The
tubing is exchanged every 6 months due to the physical wear from the systolic filter pump. The
motor start position is verified and the lenses are physically checked for any offset.
2.3.4

Projection images
To prevent excessive downsampling of the image during reconstruction an adequate number

of projections needed to be acquired to satisfy the Nyquist sampling criteria. For control dosimeters
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and IMRT this was defined at 1 degree per rotation and 360 projections allowing for multiple
reconstruction sizes to be available post-irradiation.
Figure 2-8 shows a line profile through the same dosimeter as various number of average
images was acquired.

25 imgs

10 imgs

20 imgs

9 imgs

15 imgs

8 imgs

7 imgs

Figure 2-8: Images Averaged line profiles

The projection image data was compared from 25 images to 7. A significant difference was not
recorded until 7 images were averaged. Eight images averaged per projection was recommended for
standard scans.

2.4

Discussion
Specific Aim 1 was designed to standardize the use of the DMOS-IROC as the optical CT

scanner for PRESAGE® dosimeters at IROC-Houston. A Standard Operating Procedure (SOP) was
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developed to assist users in analysis by allowing for the conditions of the imaging to be excluded
from any inconsistencies in the data. Various combinations of the variables associated with use of
the optical CT were optimized for coverage of the phantom and dynamic range of the output by
selection of flood and dark fields. Additional systematic errors such as motor position were identified
and implemented in the SOP. The camera and light source settings were set for the duration of
experiments. Reconstruction methods were finalized for different sizes of dosimeters to ensure
consistency of analysis. The following discusses each section in detail.

2.4.1

Light Source Physical Setting
The flood field for this scanner has a region of low intensity in the center. Over time we have

tried to correct this by changing the light source itself, switching diffusers and varying positioning of
both the light source and diffuser respect to one another and the telecentric lens. The current field is a
compromise between flooding the camera with the maximum amount of light in the corners of the
largest FOV to maximize the usable FOV for the tank. Losing the edges of the FOV does limit our
dosimeter size down from the maximum size of our tank. At this time this limitation has not been an
issue.
Refractive index fluid should not affect the flood field image but over time our floods do
change. We believe a small amount of dye from our seal at the base of the tank connecting the
rotating stage to the motor is coloring the fluid and changing the base optical density. As multiple
users are changing the matching fluid composition for different batches of dosimeters this
discoloration is difficult to track. When the dynamic range is no longer useful, the matching fluid is
completely replaced with new, un-dyed chemicals. Observing the change in flood fields estimates
when the changeover must happen. Major changes to the scanner, including fluid change, must be
done when no users are between a pre and post scan.
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2.4.2

Camera Field of View
The user defined camera FOV and consequently the center of rotation for reconstruction was

successfully implemented in our group. Each dosimeter that does not fit in a pre-defined FOV is
imaged and the center of rotation is documented in a universal spreadsheet each user accesses from
the DMOS-IROC computer. This system has increased reproducibility as the center of rotation input
for a certain size dosimeter is not user-dependent.
2.4.3

DMOS-IROC Quality Control
The checklist for quality control has decreased image acquisition errors and prevented scanner

malfunctions. With several users in the lab the quality control ensures that from user to user the
system is properly functioning and the flood image is not drifting. A drifting flood image can disrupt
an experiment if the flood changes from pre to post scan minutely. On a larger scale a narrowing
dynamic range might not be caught until a user cannot image an irradiated dosimeter at a dose
expected to be within range for the optical CT.
2.4.4

Projection Images
In this experiment the number of projection images was changed until an acceptable balance

between acquisition time and signal to noise ratio was reached. The time limiting factor in imaging
and reconstruction of a dosimeter is acquiring the projection images. For example, the standard scan
defined in this study (8 images averaged for 360 projections with a 1 degree rotation) imaged a
dosimeter in less than 15 minutes. In total, with the correct matching index fluid, a dosimeter could
be imaged and reconstructed in 20 to 25 minutes total. For studies requiring multiple irradiations for
reproducibility, a short imaging time was needed to keep the signal from the dosimeter comparable.
Literature has demonstrated for PRESAGE® the dose response changes over the time and can
increase rapidly in the first few hours post-irradiation (18, 20). By minimizing the imaging time
multiple dosimeters can be directly compared. Also, for a remote facility the shorter imaging times
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can increase the number of dosimeters that are imaged in a workday and can increase productivity in
a busy quality assurance program.
With this investigation completed we could begin to irradiate phantoms and determine the
change in optical density in a consistent fashion.
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3 Chapter 3 - Specific Aim 2
3.1

Rationale
The second specific aim was to assess the capability of PRESAGE® dosimeters for remote

quality assurance. IROC-Houston operates a remote quality assurance program that includes a
sizeable mail out anthropomorphic phantom program. PRESAGE® would be an excellent addition to
this program to provide three dimensional data for the only “end to end” in IROC-Houston’s
program (38). For this test to be successful, the PRESAGE® dosimeters need to withstand the unique
conditions remote dosimetry entails. These conditions include using a single batch for multiple
phantoms (ordering one large batch to fulfill several phantom shipments at a time), independence
from temperature variations due to shipping and the time elapse from manufacturing to final analysis
inherent in remote dosimetry.
The second specific aim was separated into four sections:

3.2
3.2.1

•

Creating a dose calibration scheme

•

Determining the age dependence of the dosimeter

•

Determining the temperature dependence of the dosimeter

•

Determining the effect of the readout procedure

Methods
Dose Calibrations
Dose calibrations had to be performed for every batch of dosimeters received as previously

mentioned in the introduction. The batches varied from one to 10 dosimeters. PRESAGE®
calibration curves are approximately linear (16) and only three or four dose points were necessary to
find the curve. Two methodologies for dose calibrations were examined. One method used a large
cylindrical dosimeter similar to a head and neck phantom dosimeter (9 cm diameter by 6 cm height)
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while the second method used cuvettes (1 cm x 1 cm by 4 cm container of PRESAGE® seen in
Figure 3-3). Large volume dosimeters and cuvettes have different cure rates during manufacturing
and there is some concern this might cause a change in dose sensitivity (39). Cuvettes are read out
using a Genesys 20 Visible Spectrophotometer (Thermo Scientific, Philadelphia PA) but there is no
equivalent for a large volume dosimeter. A relative dose measurement using film was devised to
measure absorbed dose.
A film phantom (shown in Figure 3-1) was created by cutting a cylinder of PRESAGE®
dosimeter material into three pieces. By using PRESAGE® in place of solid water phantom material
a correction factor was not needed (40). The pieces were labeled and marked for orientation. The top
piece was 1.67 ± 0.05 cm while the thickness of the middle piece was 1.76 ± 0.05 cm. Three pieces
of Gafchromic EBT2 film were used for the irradiations. One piece of film was taped to the top of
the dosimeter, one piece between the top and middle sections, and one piece between the middle and
base sections. An example of the film is shown in Figure 3-2.

Figure 3-1: The film phantom for dose calibrations was created from a used PRESAGE® dosimeter.
Film was sandwiched between the two levels and compared to a dosimeter from the batch of
PRESAGE® being calibrated.
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Figure 3-2: An example of a film irradiated wtih overlapping dose areas which created 4 dose levels for
the calibration curve.

The film was cut to fit the shape of the cut dosimeter. This PRESAGE®/film dosimeter was placed in
a water phantom with 5 cm of water above the surface to the top section. A radiation beam was
positioned to treat half of the phantom, and a dose of 1.8 Gy was delivered to the level of the
uppermost film. The collimator was rotated 90° and a dose of 4.8 Gy was delivered to half of the
phantom. In this manner, four different dose levels were created (see Figure 3-2). Different areas of
the dosimeter received different dose levels such that a calibration curve was acquired with 8 dose
points. The doses delivered at depths in the dosimeter were also estimated from standard water
phantom data and were corrected for the presumed electron density of PRESAGE®.
A PRESAGE® dosimeter made from Batch 01-13 of 9 cm diameter and 6 cm height was
irradiated in exactly the same fashion as the PRESAGE®/film phantom. The dosimeter was placed
in a water phantom with 5 cm of water above the surface of the dosimeter. Two beams were
delivered with a 90° rotation between exposures, so that regions of four dose levels were created.
This procedure was followed for each new batch of PRESAGE®.
The film batch was calibrated separately from the PRESAGE® irradiation. The film was set
at dmax in a 6MV beam with 9 cm of water equivalent plastic as backscatter and 1.5 of water
equivalent plastic buildup. The table was raised until the top of the solid water phantom was at 100
cm SSD with a field size of a 35 cm x 35 cm. The machine was programmed to deliver at 600
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MU/min

at

the

amounts

listed

in

Table 3-1.

square

MU

1

50

2

150

3

200

4

250

5

350

6

450

7

550

8

650

9

750

10

950

11

1150

12

1350

Table 3-1: MU delivered to each film square

The first set of MUs was delivered, and then the room was entered to remove the corresponding film
square. The machine was reset to deliver the MU needed to reach the next level and the
corresponding square was removed. This was repeated until twelve pieces of film had been
irradiated, one to each of the intended MU settings listed in Table 3-1. One square of film was left
unirradiated to serve as background. The dose delivered was calculated by hand using the machine
specific output factor of 1.095 for the 35 cm x 35 cm field size.
The film was read on a CCD Microdensitometer between 24 and 36 hours post-irradiation.
The film measurements were corrected for the flat field response of the microdensitometer with a
field of view of 150 cm2. ImageJ (NIH, Bethesda, MD) was used to analyze the film images. The
mean value of the center of the film squares was measured 3 times with the average used as the
optical density. The dose delivered was then plotted against the measured optical density and a third
degree polynomial fit was applied.
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MATLAB® was used to analyze the reconstructed dose distribution recorded by the
PRESAGE® calibration dosimeter and the mean optical density per cm of the dose regions of
PRESAGE® in the planes where the films from the film phantom are located was recorded. The film
dose calibration curve was used to convert the film’s optical density to dose using IROC-Houston’s
protocol. The OD measured from the PRESAGE® large volume calibration dosimeter was plotted
against the measured film dose to create a linear dose calibration curve.

Figure 3-3: The high-impact phantom containing a cuvette cutout (left) with cuvettes inserted. A close
up of the cuvettes is shown on the right.

An initial experiment to check the linearity of PRESAGE® was performed using the dose
levels listed in Table 3-2 to follow the film dose levels as closely as possible. Cuvettes with a
volume of 1 cm x 1 cm x 4 cm and containing PRESAGE® of batch 10-12 were irradiated in high
impact polystyrene. A cutout to contain 4 cuvettes was sandwiched between slabs of solid water to
allow for 1.5 cm buildup and 9 cm backscatter placed in a 35 cm x 35 cm field size. The absorption
of the material was read using a Genesys 20 Visible Spectrophotometer prior to and post irradiation
and the change in absorption per cm was compared to the dose delivered to the center of the cuvette
to calculate the PRESAGE® calibration. Readings were taken 3 times for each cuvette and the
average reading was recorded.
One cuvette was irradiated to each dose level. Two additional cuvettes were irradiated to
two of the originally-selected dose levels (450 MU and 650 MU) to test reproducibility. The dose
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was calculated from the MU delivered and the change in optical density was plotted versus the dose
delivered.

Cuvette #
1
2
3
4
5
6
7
8
9
10
11
12

Cuvette
MU
50
150
200
250
350
450
550
650
750
850
650
450

Table 3-2: MU delivered to 12 cuvette study

A comparison between large volume and cuvette calibration was performed using a single
batch of dosimeters.

For this study, dosimeters of Batch 01-13 were used.

A large-volume

PRESAGE® dosimeter of dimensions 9 cm diameter by 6 cm height was irradiated in the same
fashion, using two beams with a 90° rotation, as was described above. The MU delivered to the large
volume dosimeter were 0 MU, 200 MU , 650 MU and 850 MU in each respective quadrant. The
cuvettes received a similar MU delivery with 50 MU, 200 MU, 650 MU and 850 MU. The procedure
was detailed above. Each dose was calculated and plotted together to compare the slope of the
respective measured calibrations. The difference was then quantified.

3.2.2

Age and Temperature Dependence
One concern with remote dosimetry is whether it is feasible to have physicists at other sites

store dosimeters under the same conditions as at IROC-Houston. The loss of control over the storage
and handling conditions at the site to be evaluated can affect the results. This experiment was done
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with two separate batches of PRESAGE® and tested the effects of different storage temperatures,
extreme shipping temperatures and extreme irradiation temperatures using dosimeters which were
recently manufactured and dosimeters manufactured 3 or 4 months before irradiation. Each separate
experiment was analyzed as a standalone data set and as an overall dataset (where applicable).
The first experiment tested the difference in measured change in optical density from
dosimeters that were irradiated in the same conditions but stored after irradiation at either at 3°C or
room temperature (≈22.7°C). Upon receipt from the manufacturer, the dosimeters were placed in a
refrigerator for storage prior to irradiation. Each dosimeter was irradiated under the same conditions
at different times: within 1 week of receipt from the manufacturer and at 3.5 months post receipt
from the manufacturer. The dosimeters were irradiated in a water phantom using a Varian 2100
machine (Varian Medical Systems, Pal Alto, CA.) The machine was set to 400 monitor units at 6
MV to irradiate the center of the dosimeter with the gantry set at 270°, 10 cm of water proximal to
the dosimeter and 9.5 cm of backscatter. Up until irradiation the dosimeters were stored at 3° and
brought to room temperature for the irradiation. After irradiation all dosimeters were imaged for a
baseline reading. One dosimeter was returned to a cold environment (labeled “SC” for stored cold)
and the second dosimeter was left at room temperature (labeled “SR” for stored at room
temperature.)
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Figure 3-4: Set up for storage and temperature irradiations.

The dosimeters were imaged at room temperature and at varying times over several weeks
with the time noted in days since irradiation. The imaging system was the DMOS-IROC (22) and the
scanning procedure was described in more detail in Chapter 2. All dosimeters were imaged with 1°
rotation for 360 steps with a flood and dark correction. Reconstruction was done with a 2 mm slice
width and a Hamming filter. Every dosimeter was imaged prior to irradiation (referred to as a prescan). The pre-scan and post-scan (considered to be any imaging done post-irradiation) were
subtracted prior to full reconstruction. This eliminated un-irradiated sections of the dosimeter from
the final measured dose volume. The center slice of the dosimeter was measured in MATLAB and
the mean change in optical density was plotted against the time from irradiation.
For remote dosimetry, shipping is of great concern for the stability of the dose measurement.
It has been shown that storage in cold temperatures minimizes post-irradiation change in dose
response and increase the stability of the dosimeter (20). Four dosimeters were used in this study.
Two were exposed to extreme cold conditions (≈ -18°C) by staying in the freezer for 24 hours while
the other 2 were exposed to extreme hot (maximum 66°C) by staying on the dashboard of a car
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parked in the sun for 24 hours. Two dosimeters experienced the extreme condition prior to
irradiation (one to extreme cold conditions and one to extreme hot conditions) while the other two
dosimeters were exposed to the extreme conditions post irradiation. The stability of the reading was
measured over time with the dosimeters stored at 3°C between readings. All irradiations and
readings were conducted at room temperature. The irradiation and imaging settings were the same as
stated above.

Figure 3-5: Dosimeters being brought to extreme cold or hot for irradiation. The equilibration was done
in a water bath for irradiation.

The last condition investigated in the temperature study was the effect on response of the
temperature of the dosimeters during irradiation. This experiment simulated the situation when an
irradiation is performed without a dosimeter being brought to room temperature. This could occur
with an irradiation shortly after receiving a dosimeter or when removing a properly stored dosimeter
for an onsite irradiation.
Three dosimeters were used for this experiment. All dosimeters were stored at 3°C upon
receipt from the manufacturer and between every post scan. The dosimeters were pre-scanned and
one was placed in ice water (≈3.5°C), a second wrapped in hot packs prior to being placed in hot
water (≈35.6°C) as see in Figure 3-5, and the third dosimeter was kept at room temperature. All three
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irradiations were performed as described above. All dosimeters were then brought to room
temperature and post-scanned using the same settings described previously. The dosimeters were
scanned repeatedly over about 25 days to record the changing OD over time. The same post-scan
settings were used as described above and the dosimeters were at 3°C and brought to room
temperature for every scan.

3.2.3

Readout Procedure
Over the course of the extended time experiments the dosimeters were placed in a 633±5 nm

wavelength for 16 – 18 scans (including pre-scans). Each scan exposed the dosimeter to 15 minutes
of red light at minimum. This experiment evaluated the effect of exposure to the red wavelength. An
unirradiated dosimeter was placed in the DMOS-IROC and the pixel value through the center of the
dosimeter was recorded over 5 hours to record any change in OD due to the scanning procedure.

3.3
3.3.1

Results
Dose Calibrations
The film calibration results are shown in Figure 3-6. The film demonstrated a response to

dose that can be described with a polynomial as OD = 0.0004x3 -0.0137x2 + 0.1542x where x is the
dose delivered in Gy. Large volume PRESAGE® calibrations were performed for all phantom
experiments. These results were for PRESAGE® Batch 01-13 which was used to compare to the
cuvette calibration technique. Three films were irradiated at each dose level. The largest standard
deviation was observed at 7.1Gy and was 0.003 OD or 0.5 %.

OD
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Figure 3-6: Film Calibration for film used in PRESAGE® calibration phantom and HN phantom
irradiations. Error bars indicate one standard deviation.

The PRESAGE® “large volume” calibration was performed with three dosimeters of Batch
01-13. The experiment used 2 depths for dose measurements and 8 total dose points. The results are
shown in Figure 3-7 where the slope of the dose response curve, determined from 3 repeat
measurements, was 0.0319 ± 0.015 ∆OD ∙ Gy−1 ∙ cm−1 . As was described in Section 1.3.1, the
response of PRESAGE® is described in terms of an optical attenuation coefficient, OD • cm-1, to

enable construction of a map of OD measurements. The calculated dose estimates varied up to 10%
from the film measurements and were not considered reliable for dose calibrations.

D O D / cm
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Figure 3-7: PRESAGE® Batch 01-13 Dose Response

The results of the linearity study performed using 12 cuvettes containing PRESAGE® from
batch 10-12 are shown in Figure 3-8. The slope showed to be linear through almost 10 Gy covering
any hot spot anticipated in QA phantom studies. The cuvettes irradiated to the same dose point at

D O D / cm

different times were within the uncertainty of the measurement.

Figure 3-8: 12 Dose Response of Cuvettes Containing PRESAGE®

D O D / cm
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Figure 3-9: Dose Response of Cuvettes Containing PRESAGE® Batch 01-13

The cuvette calibration of Batch 01-13 (Figure 3-9) measured a dose response curve with a
slope, determined from 3 repeat measurements, of 0.0255 ± 0.003 ∆OD ∙ Gy−1 ∙ cm−1 . This differed

from the large volume dose by 0.006 ∆OD ∙ Gy−1 ∙ cm−1 . The effect of differing slopes is illustrated

in Figure 3-10. The steeper slope of the large volume dose response shows a greater sensitivity to
dose than the cuvettes. At lower doses, below 4 Gy, the data suggested the two measurements fell
within the others’ uncertainty. At larger doses, the curves continue to diverge suggesting that the

largest dose delivered in a HN phantom study (discussed in greater detail in Specific Aim 3) would
not be properly related to OD • cm-1 by the cuvette calibration method.

D O D / cm
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Figure 3-10: Batch 01-13 Dose Response Comparison

3.3.2

Age and Temperature Dependence
The storage temperature experiment followed 4 dosimeters over approximately 15 to 25 days

and is shown in Figure 3-11. The dosimeters stored at colder temperatures showed an increase in OD
over time regardless of the age of the dosimeter at irradiation. The dosimeters stored at room
temperature showed an initial increase in pixel values followed by a fading of signal. The older

D OD / mm

dosimeter began to fade near day 4 while the newer dosimeter did not begin to fade until day 11.

Figure 3-11: Storage Temperatures with repeated post scans over time.

D OD / mm
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Figure 3-12: Temperature changes prior to and post irradiation

In Figure 3-12 the control dosimeter was the same dosimeter irradiated for the storage
experiment described in Figure 3-11 in the previous section and is shown in blue diamonds. Both the
dosimeters exposed to freezing temperatures (shown in circles and triangles) and the dosimeter
exposed to heat prior to irradiation (depicted in squares) trended well with the control. The dosimeter

D OD / mm

exposed to heat after irradiation initially agreed with the others but quickly faded off.

Figure 3-13: Temperature changes at irradiation

∆ O ∆ / cm
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Figure 3-14: Initial Readout with Varying Irradiation Temperature

As shown in Figure 3-13, the readings taken on the day of irradiation showed large
differences. This is in contrast to the prior experiments shown in Figure 3-12, in which the readings
taken on the day of irradiation were all quite similar. All dose response readings for the 3 irradiations
rose over time with the smallest amount of change occurring in the dosimeter that was heated during
irradiation. This smaller change could be attributed to the dosimeter’s higher initial response. In
Figure 3-14, the initial readout OD change is compared to the irradiation temperature with measured
values (points) and fitted calculations (lines). This display format was chosen to enable a comparison
of the temperature dependence of the reaction rates between our dosimeters and the cuvettes used by
Skyt et. al. (41).

3.3.3

Readout Procedure
A dosimeter that had been irradiated with a simple 4 cm square field was set in the DMOS-

IROC tank and a single live projection image was observed. The DMOS-IROC camera reported a
pixel value reading of 2400 at the exact center of the dosimeter. The pixel value is related to the light
intensity received by the CCD camera and, for dose distribution reconstructions, would be used to
calculate the OD and subsequently the dose. Pixel value observations were taken at 0.5, 1, 2, 3, 4 and
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5 hours and a constant pixel value of 2400 was observed throughout the study. Data were not taken
after 5 hours to avoid prolonged exposure to the DMOS-IROC light source from causing OD
changes to occur even in a darkened environment. The 5 hour elapsed time still encompassed the
total time a dosimeter would be exposed to the DMOS-IROC light during a scanning procedure and
through repeat scans taken to measure change in dose response over time.

3.4

Discussion

3.4.1

Dose Calibrations

Two dose calibration schemes were tested in this section: a calibration using 8 dose levels
measured in a large-volume dosimeter and a calibration using 4 small volume cuvette dosimeters.
The two methodologies both demonstrated linear slopes (expected for PRESAGE®) and gave dose
calibrations with slopes within 0.006 ∆OD ∙ Gy−1 ∙ cm−1 when compared directly using the same

batch. Investigations for large volume and cuvette calibrations were made due to possible
complications due to differences in response and methodologies.
For the large volume dosimeter the doses delivered at depths in the dosimeter were estimated
from standard water phantom data and were corrected for the presumed electron density of
PRESAGE®. As an alternative procedure, doses were measured with film. The dose measured with

film was then used to calculate the PRESAGE® ∆OD ∙ Gy−1 ∙ cm−1 . This added step introduced the

uncertainty of the film measurement, determined to be less than 1% in Section 3.3.1, to the overall

dose calibration. However, the doses estimated from standard water phantom data were considered
less reliable because, at the time of this experiment, the radiological properties of PRESAGE® were
not known with sufficient confidence.
The readout for the large volume dosimeter was done with the DMOS-IROC while a
spectrophotometer was used to analyze the cuvettes. While theoretically the same wavelength of
light was used for both the DMOS-IROC and the spectrophotometer, differences in the light
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production (LED verses prism) could have affected the OD readout and induced the differences seen
in Figure 3-10. Vidovic et. al. directly compared a smaller version of the DMOS-IROC (with 50
micron resolution called the DMicroOS using an 633 nm LED light source) to a spectrophotometer
reading (set to 633 nm) with a molded cylindrical PRESAGE® that fit within both instruments (42).
This study found a difference of 0.88% in sensitivity suggesting the modality (and the light source)
used for optical readout does not greatly affect the OD/cm measurement. A similar study with
molded cylinders would need to be performed to confirm this finding in our larger DMOS-IROC
scanner. The change in resolution is not expected to change the OD in simple open field irradiations
used for dose calibration and indicates the difference in sensitivity we found is more likely do to the
volume differences.
The cuvettes were read using a spectrophotometer whose settings do not change between pre
and post scanning. As there is no fluid involved it is easier for the user to control the measurement
environment. The cuvettes identical sizing allowed for the creation of a solid water cutout allowing
for a solid full scatter phantom for dose calibration. There is some discussion in the literature that the
volume of PRESAGE® might affect the OD change from radiation (18, 43, 44). The strength of the
lattice due to differences in cure rates for different volumes is suspected but the full reasoning at this
time is unknown and beyond the scope of this project (45). While it is currently common practice in
the community to use cuvettes for calibration of a batch of dosimeters, more investigation needs to
be performed in volume differences in dose response to use this dosimeter as an absolute dosimeter.
For this project the ability to use cuvettes was not available until near the end of
measurements. As the phantom measurements were all relative and scaled to TLD point dose
measurements, an absolute calibration was not necessary. The large volume calibration was chosen
as a starting point for all dose calibrations for consistency over the course of the investigation and as
the most accurate method due to the volume difference in the large dosimeter and the cuvettes.
Should IROC-Houston move forward with relative PRESAGE® measurements investigation towards
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the use of the cuvette calibration is advised. If lower doses are used for phantom irradiations the
sensitivity difference in calibration methodologies might not affect the final dose readout. The
cuvette calibration method is less expensive and a less time consuming process for a batch by batch
dose calibration. Also, for different anthropomorphic phantoms the shape of the dosimeter could
change away from the simple cylinder and the cuvette calibration might become the more reliable
method for calibration. If there is a known suspicion that the volume of the dosimeter changes the
sensitivity, the geometry (i.e. a long dosimeter versus a short dosimeter with different diameters)
could also change the curing rate and the sensitivity for the dosimeter. For absolute measurements
more investigation will be needed of potential volume effects.

3.4.2

Age and Temperature Dependence
Remote dosimetry depends on having dosimeters reliably record and retain dose and dose

distributions for a certain period of time after irradiation. Ideally, the recorded dose would not
change once the dosimeter has fully developed. PRESAGE® has been characterized to have
increasing signal followed by fading over time as shown in Section 3.3.2. With the dosimeter used as
a relative dosimeter and the dose scaled to a point, a change of signal can be acceptable if that
change can be characterized. In all situations, a dosimeter stored in a cold environment did not show
any signal fading. The dosimeters stored at room temperature showed measurable fading after a
certain time point (Figure 3-11). This point was dependent on the age of the dosimeter at the time of
irradiation. Remarkably, this was the only time in this study an older dosimeter showed significant
difference from a newer dosimeter. Aged dosimeters record dose correctly in a simple open field
environment. All measurements in this study were across a center slice excluding the outer perimeter
and further investigation is needed for doses closer to the edges of the dosimeters. Dosimeters need
to be manufactured close to irradiation date and not stored for months prior to sending them out for
maximum reliability.
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Temperatures can be controlled in lab settings but are almost unavoidable with remote
dosimetry. The greatest concern is the temperature variability the dosimeter might be exposed to
during the shipping process. Four dosimeters were exposed to extreme temperature situations prior to
and post irradiation to test for readout stability. All results except those from the dosimeter that was
heated post irradiation were comparable to the results from the control dosimeter. The dosimeter
heated after irradiation (which could reach 66°C) immediately faded and stayed near 0.012 OD / mm
for the duration of scans. The initial reading taken immediately post-irradiation was performed prior
to heating the dosimeter showing the dosimeter was correctly irradiated to the same dose as the other
dosimeters. Shipping dosimeters should be done with a priority method to avoid any delays that
could allow the dosimeter to reach a high internal temperature on the return trip to IROC-Houston.
Methods of temperature gauge should be researched prior to implementing remote dosimetry to
ensure the package never reached a critically high temperature. This could include a piece of film or
other small thermally reactive material. IROC-Houston anthropomorphic phantom cases are well
insulated and should not reach the critically high temperatures used in this study. But, any use of the
mail-out system to send a stand- alone dosimeter would need to be closely monitored and/or wellinsulated for the return trip.
The temperature of the dosimeter at irradiation also results in a different reading for each
dosimeter. The change in response over time was measurably different in the first 3 to 4 days and
then response increase appeared to continue at the same rate regardless of irradiation temperature.
By using PRESAGE® as a relative dosimeter, the uncertainty in dose response can be lessened by
requesting all dosimeters are irradiated at room temperature and ensuring the calibration dosimeter is
also irradiated at room temperature.
More studies are needed to characterize the fading point (in time) of different aged
dosimeters. Due to the cost of the dosimeters and limited amount of dosimeters that can be made
from a single batch this is a difficult prospect for the large volumes. As every batch of dosimeters
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potentially has a different sensitivity it can be assumed the fading characterization could also change.
To characterize fading over time in large volumes would be a separate project. Skyt et. al. (41) have
performed a similar study using cuvettes. Figure 3-14 was the only direct comparison made between
the two studies. With different dose prescriptions and PRESAGE® batches the data was not expected
to exactly reproduce. The large volume OD change with temperature trended well with the published
cuvette results. The cuvette data showed the same trend of dosimeters stored at higher temperatures
increasing in OD until near the 10 day mark and then decreasing. Lower temperatures continued to
increase without reaching a threshold. This corresponded with the new dosimeters tracked in Figure
3-11. The older dosimeter began to fade much sooner (near day 3) implying dosimeters were better
used as close to manufacturing as possible. If dosimeters are returned prior to the fading point they
can be readout with a corresponding calibration. Otherwise, the fading of dosimeters would need to
be characterized to know if the intrabatch fading is equal. The calibration dosimeters should be kept
in the same thermal situation as the experimental dosimeter to minimize differences. While
PRESAGE® is not yet capable to be an absolute dosimeter, keeping the calibration close to the
experimental dosimeter is good practice to minimize the relative correction as the field moves
towards using 3D dosimeters for absolute dose measurements (28, 43, 46).
Volume effects of PRESAGE® response have been discussed in several studies (41, 43)
questioning if there are differences due to the different rates in curing and polymer strength and how
great an impact this could make on measurements. This study investigated whether using a larger
volume greatly affected the response characterized in cuvettes. Cuvettes were analyzed using a
spectrophotometer as opposed to optical CT introducing a different light spectrum and no reliance on
a CCD camera. Any of these variabilities could cause a discrepancy making cuvettes unreliable for
characterizing large volume PRESAGE®. This study analyzed the volume appropriate for remote
phantom dosimetry in the same optical setup used for phantom studies to reduce readout variabilities
not induced by temperature or time. The data’s agreement with cuvette data was acceptable to make
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the case for using cuvettes to model the large volume dose response at doses below 4 Gy. This
further backed up the recommendation made earlier to continue future dose calibration with the
cuvette method if the dose prescription is lowered. As formulations mature and characterizations
need to be re-examined for validity, the cuvette method is less time consuming and could carry the
majority of the data though a larger volume dataset should also be analyzed to verify the volume of
the dosimeter is not affecting the dose readouts.

3.4.3

Readout Procedure

To ensure none of the OD readouts from the age experiments were falsely increased by the red
light exposure a measurement of the OD change of a dosimeter not exposed to ultraviolet or ionizing
radiation was performed. There was no change measured in 5 hours of constant exposure that
exceeded the time any of the dosimeters in the former experiments were placed in the scanning tank.
This was expected and removed the need to account for red light exposure in the previous results. In
most situations a dosimeter would never reach the 5 hour mark in a tank and this experiment was
solely to validate the age experiments where multiple post-scans were necessary.
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4 Chapter 4 – Specific Aim 3
4.1

Rationale
As treatment plans become more complex, it is increasingly difficult to assure the intended

calculated dose is being delivered correctly. Using a volumetric dosimeter in quality assurance for
complex treatment plans gives the user a large increase in information as compared to planar films.
This means that by using the 3D measurement data set, more robust comparisons to the TPS can be
made. Currently, IROC-Houston uses film planes and TLD to evaluate phantom irradiations. The
film measurements are analyzed using a 2D gamma with 7%/4mm passing criteria (discussed in
more detail in the introduction). Literature has shown this may or may not be an appropriate passing
criterion for a 3D dataset (27). As part of this specific aim, various gamma constraints were
calculated to identify a relevant constraint for properly delivered treatment plans using 3D dose
measurements.
The previous experiments were designed to test the optical CT scanner and the PRESAGE®
dosimeter separately. This section uses the system as a whole. Treatment plans were created which
ranged in complexity from simple open fields to complex, clinically relevant plans for IMRT. Each
plan was compared against film and TLD measurements and the TPS. Gamma index analyses with
various constraints were applied for comparison to assist in choosing appropriate constraints for
evaluation.
The third specific aim is separated into three sections:
•

Irradiating the phantom with open field plans

•

Irradiating the field with IMRT plan

•

Modifying gamma analysis constraints
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4.2
4.2.1

Methods
Open field plan
To begin, simple open field treatment plans were created using the IROC-Houston HN

phantom to confirm that the dosimetry system was able to verify the TPS prior to working on
complex plans. The HN phantom was developed by IROC-Houston to credential institutions
participating in certain RTOG clinical trials (47). The film/TLD insert contains 8 TLD capsules and
2 planes of Gafchromic EBT2 film. Figure 4-1 shows the cylindrical insert used for imaging and an
axial CT slice with labeled structures in the film plane. The phantom was designed with two primary
target volumes (PTV) and a critical structure to avoid. Eight TLD capsules were placed in the insert:
4 in the primary PTV, 2 in the secondary PTV and 2 in the critical structure. Half of the TLDS were
2 mm inferior to the axial film and half of the TLDs were 2 mm superior to the axial film. A piece of
film bisected the primary PTV. A second insert was used to hold a PRESAGE® dosimeter in the
same area as the imaging insert. Figure 4-2 and Figure 4-3 show the separate inserts with contours
from the TPS.

Figure 4-1: The HN phantom and imaging insert (left). A CT slice of the imaging insert with labeled
structures (right).
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The HN phantom was scanned using a GE LightSpeed RT16 CT scanner. One scan was
performed using a film/TLD insert (Figure 4-2) and a second scan was performed using the
PRESAGE® insert (Figure 4-3). Both scans were imported into the Pinnacle3 TPS (version 9; Philips
Healthcare, Fitchburg, WI). Localization was performed with 3 BBs: two placed in the ears and one
placed on the tip of the nose. Internal structures and the TLD capsules were contoured. These
contours were used for every treatment plan evaluated in this study.

Figure 4-2: film/TLD Insert with structures and TLD contoured
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Figure 4-3: PRESAGE® Insert with the dosimeter surface contoured (orange) and a second contour
drawn 5 mm inside the surface of the dosimeter (green)

A single plan was created and the dose distribution was calculated using the two sets of CT
scans. The plan created on the film/TLD insert was moved to the CT image set of the PRESAGE®
insert for analysis. The plan had a 2 beam configuration: anterior-posterior (AP) and right-lateral
(RL) referred to as the APRL plan from here on. This plan prescription delivered 500 cGy to the
isocenter delivered with 60% (361 MU) of the dose in the AP direction and 40% (226 MU) in the RL
direction with the phantom aligned to the BBs. These plans were exported and used for analysis with
the PRESAGE® irradiations.
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Figure 4-4: Phantom setup with laser alignment to BBs

Six irradiations were performed using the APRL plan using a Varian 600 machine. The
film/TLD insert was irradiated 3 times using 3 sets of dosimeters. The PRESAGE® insert was also
irradiated 3 separate times with 3 separate dosimeters. The phantom was aligned on the treatment
table using the alignment BBs as shown in Figure 4-4. The plan was delivered in QA mode through
the MosaiQ delivery system (Elekta AB, Stockholm, Sweden). The film/TLD and PRESAGE®
dosimeters were all irradiated in the same session.
A large volume PRESAGE® calibration (methodology described in detail in Section 3.2.1)
was performed with MU inputs of 0, 300, 600 and 900.
The TLDs were read 15 days post-irradiation. After calculating the dose (described in detail
in Section 1.4.1) the ratio for measured dose versus calculated dose from the TPS was taken. A value
between 0.95 and 1.05 was considered passing. Reproducibility was checked using the coefficient of
variance and a value less than 3% was considered acceptable for the purpose of this project.
Statistical significance was checked using a one-sample t-test with α = 0.05 as the significance level
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and a null hypothesis of µ0 = 0.949. The Excel function TDIST was used to calculate the p-value (the
probability of rejecting the null hypothesis), which needed to be less than 0.05 to be statistically
significant.
The films were scanned 2 days post-irradiation with a CCD Microdensitometer for
Radiochromic Film (Model CCD100 Photelectron Corporation, Lexington, MA). An un-irradiated
piece of film from the same batch was scanned to correct for background dose and non-uniformities
in the densitometer response. A 1 cm grid was imaged for spatial calibration. The irradiated films
were imaged, spatially calibrated and corrected before being saved as FIT files. The film image file
was then loaded into IROC- Houston internal software and registered to the phantom plan using
registration pinpricks that were applied when the film was first loaded into the phantom. The dose
calibration curve for the film was applied and the dose was scaled relative to the TLD readings in the
PTV. The film was registered to the treatment plan calculated using the film/TLD insert CT scan.
Three dose profiles were taken and their locations are shown in Figure 4-5. Two profiles were taken
on the axial film: a right–left profile bisecting the secondary PTV structure and PTV and a superiorinferior profile bisecting the PTV. The third profile was also a superior-inferior profile bisecting the
PTV taken on the sagittal film. The 2D gamma analysis at 5%/3mm distance to agreement (DTA)
was performed on both films over the entire film area. Pinpricks and the separation area for the
sagittal film were removed from the calculation area to account for user-generated discrepancies.
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Figure 4-5: Film Profile locations

The PRESAGE® dosimeter was scanned with the DMOS as described in section 2.3.2 using
the settings in
Table 4-1.
Scan Settings
Degrees Rotation
Number Projections
Number Images Averaged
Flood/Dark Image Average
Reconstruction Settings
Voxel Edge (mm)
Center of Rotation
Filter

1
360
8
200

1
585
Ram
Lak

Table 4-1: DMOS Settings for HN Phantom Irradiations

The PRESAGE® optical density cube was uploaded to a CERR file containing the treatment
plans calculated on both inserts. At this point, the CERR file contained the treatment plan and
contours from the film/TLD insert, the treatment plan calculated using the PRESAGE® insert and the
change in optical density from the PRESAGE® dosimeter. The optical density files were initially
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calibrated using the large volume dose calibration curve for the batch. The image fusion function
was used to fuse the PRESAGE® dose reconstruction to the PRESAGE® scan. The dose at each TLD
point was recorded and compared to the average measured TLD dose for the irradiation and the
PRESAGE® dose was scaled a second time to the measured dose.
Dimension

Coordinates

Sagittal (x-axis)

-1.35 cm

Coronal (y-axis)

-11.80 cm

Axial (z-axis)

-25.99 cm

Table 4-2: CERR coordinates for 2D Gamma Comparison

Dose profiles were taken along the same 3 locations as the film (Figure 4-5) for comparison.
A 2D gamma at 5%/3mm was taken in the axial and sagittal planes matching the film planes and also
the coronal plane through the center of the PTV (described in Table 4-2). A 3D gamma at 5%/3mm
was taken for the whole PRESAGE® dosimeter with a 5 mm contracted contour to reduce the effect
of the edge artifact.
4.2.2

IMRT Plan
A 9 beam IMRT plan was created using the dose prescription in Table 4-3. This prescription

was modified from the current instructions for the HN phantom provided by IROC-Houston to
institutions wishing to be credentialed for clinical trials using the HN phantom. The secondary PTV
was changed to the “parotid” and the dose was lowered to coincide with dose values quoted by
Dijkema et al (48). The parotid was added to the plan to provide a normal tissue to predict tumor
control in a later study.

Primary PTV
Parotid
Organ at risk
Normal tissue

6.6 Gy to at least 95% of the PTV
< 1% of the PTV receives < 93% of the prescribed dose.
3 Gy to at least 95% of the PTV and
< 4.5 Gy, maximum dose.
≤ 110% of the prescribed dose (6.6 Gy).
Table 4-3: IMRT Dose Prescription
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Six irradiations were performed using the IMRT plan. As stated in the previous section, the
film/TLD insert was irradiated 3 times using 3 separate sets of dosimeters and the PRESAGE® insert
was irradiated 3 separate times using 3 separate dosimeters. The phantom was aligned on the
treatment table using the alignment BBs and the treatment plan was delivered in QA mode through
the MosaiQ delivery system The film/TLD and PRESAGE® dosimeters were all irradiated in the
same session.
A large volume PRESAGE® calibration (methodology described in detail in Section 3.2.1)
was performed with MU inputs of 0, 200, 650 and 850. The TLDs were read 16 days postirradiation. At this point the methodology was the same as described for the APRL irradiations.
4.2.3

Gamma Constraints
This study was designed to define an appropriate gamma constraint and passing percentage

(percentage of pixels passing at a certain constraint) for the PRESAGE® dosimeter which has not
been defined in literature. Varying gamma constraints allowed a comparison of percentage of
passing pixels from different gamma indexes between the different constraint levels and between the
different dosimeters. The initial analysis was performed using a gamma constraint of 5%/3mm DTA
to test the hypothesis. Two more gamma constraints were studied: 3%/3mm DTA for its prevalence
in the clinic (5) and 7%/4mm DTA for its current constraint for IROC credentialing .
The gamma index was calculated as described above in Section 1.5. Additionally, the
passing percentage for each contoured structure was recorded.
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4.3
4.3.1

Results
Open Field Results

The average TLD dose from all three trials for the APRL plan is listed in Table 4-4.

TLD Location

Measured
Dose (cGy)

Predicted
Dose (cGy)

Measured/Predicted
Dose

COV

PTV Sup Post

530

528

1.00

0.76%

PTV Inf Post

530

519

1.02

1.48%

PTV Sup Ant

530

526

1.01

1.61%

PTV Inf Ant

533

521

1.02

0.63%

Cord Superior

496

486

1.02

0.67%

Cord Inferior

492

479

1.03

1.37%

Parotid Superior

497

495

1.00

0.43%

Parotid Inferior

496

490

1.01

1.15%

Table 4-4: Average TLD Results from 3 APRL Irradiations

The ratios of the measured to predicted doses all range from 1.00 – 1.03 and are within the pass rate
of 0.95 – 1.05. The COV values for all TLD are below 3%.
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Figure 4-6: Right-Left film profile from Trial 1 of APRL plan
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Figure 4-7: Superior-Inferior film profile from Trial 1 of APRL plan
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Figure 4-8: Anterior-Posterior film profile from Trial 1 of APRL plan

The film profiles taken from trial 1 in the locations shown in Figure 4-5 are displayed in Figure 4-6
through Figure 4-8. The film area was smaller than the radiation field and dose fall off was not
measured. Other than a 5% difference at the edge of the RL profile (attributed to pressure marks on
the film seen in Figure 4-9) the measured dose stayed within 1% of the calculated values.

Figure 4-9: 2D Gamma results for film at 5%/3mm in the axial (left) and sagittal (right) planes for Trial
1 of APRL Plan

The average over all 3 trials for the 2D gamma had 88% pixels pass at 5%/3mm in the axial
plane and 93% pass in the sagittal plane. Full results from each trial are listed in the Appendix.
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The large volume calibration resulted in a dose response of 0.0599 ± 0.003 ∆OD ∙ Gy−1 ∙

cm−1 and is shown Figure 4-10. The calibration was applied to the convert the OD to dose for the

PRESAGE® and then the dose was normalized to the TLD in the PTV.
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Figure 4-10: Dose Response for APRL PRESAGE® Batch

The matching line profiles from the imaging insert are shown in Figure 4-11 through Figure
4-13. The largest discrepancy of 4.7% appeared near the edge of the dosimeter. In other locations the
doses were within 1%.
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Figure 4-11: PRESAGE® Right-Left dose profiles for APRL plan
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Figure 4-13: PRESAGE® Anterior-Posterior profiles for APRL plans

The gamma results measured using 5%/3mm criteria for all three trials are summarized
below in Table 4-5. The column labeled PRESAGE® contains the 2D gamma results in the planes
specified. The last column shows the average for the 3D volume of the PRESAGE® minus the 5 mm
edge artifact.
Area of
PRESAGE®
Film
PRESAGE®
Interest
3D - 5mm
88±3.2%
97±0.6%
X
Axial
93±1.2%
99±0.9%
X
Sagittal
X
99±0.9%
X
Coronal
X
X
94±0.7%
Volume
Table 4-5: PRESAGE® average gamma results at 5%/3mm for APRL plans

The gamma results for the axial film plane (88% pixels passing) were 9% lower than for the axial
PRESAGE® plane (97% pixels passing) and varied as much as 6.4% across 3 trials. The sagittal and

62
coronal planes as well as the volumetric gamma results all demonstrated pixel passing rates at or
above 93%. The variation of the measurements stayed in a range of ±1% across all the trials.
4.3.2

IMRT Plan Results
The average TLD results for all 3 trials for the IMRT plan are listed below in Table 4-6.
TLD Location

Primary PTV Sup Post
Primary PTV Inf Post
Primary PTV Sup Ant
Primary PTV Inf Ant
Organ at Risk Sup
Organ at Risk Inf
Secondary PTV Sup
Secondary PTV Inf

Measured
Dose (cGy)
668
689
682
686
315
300
302
329

Predicted
Dose (cGy)
686
688
688
690
318
300
308
333

Measured/Predicted
Dose
0.97
1.00
0.99
0.99
0.99
1.00
0.98
0.99

COV
0.73%
1.68%
0.95%
0.98%
0.72%
2.52%
1.48%
2.33%

Table 4-6: Average TLD Results for IMRT Plan

The ratios of measured TLD results were between 0.97 and 1.00 and remained within the pass rate of
5%. The COV stayed below 3%.
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Figure 4-15: Superior-Inferior film profile for Trial 1 of IMRT plan
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Figure 4-16: Anterior-Posterior film profile for Trial 1 of IMRT plan
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Figure 4-14 through Figure 4-16 are the film profiles results for Trial 1. The superior-inferior
profile showed a 2 mm difference DTA near the superior edge of the dose plane and the anteriorposterior profile showed a 1 mm difference in DTA through the organ at risk. There was no DTA
difference in the right-left profile.

Figure 4-17: 2D Gamma results for film at 5%/3mm in the axial (left) and sagittal (right) planes for
Trial 1 of IMRT plan

The average 2D gamma had 93% pixels pass using 5%/3mm criteria in the axial plane and
90% pass in the sagittal plane. Full results from each trial are listed in the Appendix.
The large volume PRESAGE® dose calibration resulted in a dose response 0.0292 ± 0.015
∆OD ∙ Gy−1 ∙ cm−1 and is shown in Figure 4-18.
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Figure 4-18: Dose Response Curve for IMRT PRESAGE® Batch

The dose line profiles for the PRESAGE® dosimeters are shown in Figure 4-19 through Figure 4-21.
All 3 trials of PRESAGE® measurements are shown in the graphs. The dose calibration curve was
applied and then the dose was normalized to the TLD in the PTV. Good agreement was seen in
comparison to the treatment plan which is shown by the blue curve.
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Figure 4-19: Right-Left PRESAGE® profiles for IMRT plan
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Figure 4-21: Anterior-Posterior PRESAGE® profiles for IMRT plan

The gamma results using a 5%/3mm criteria for all three trials are summarized below in
Table 4-7.
Film

PRESAGE®
Slice

%difference

PRESAGE

Axial
93±1.4%
95±2.6%
2.3%
X
Sagittal
90±2.6%
96±2.0%
6.0%
X
X
Coronal
X
X
98±1.1%
X
X
X
96±2.0%
Volume
Table 4-7: PRESAGE® average gamma results at 5%/3mm for the IMRT plan

The column labeled PRESAGE® contains the 2D gamma results in the planes specified. The
last column shows the average for the 3D volume of the PRESAGE® minus the 5 mm edge artifact.
The film passes at or above 90% at the criteria of 5%/3mm in both planes. The PRESAGE® passing
results are higher by 2% in the axial plane and 6% in the sagittal plane with at least 95% pixels
passing at 5%/3mm for a 2D slice from the PRESAGE® dosimeter. The 3D gamma had 96% pixels
passing. Uncertainties are reported to two significant figures based on the precision of data reported
by CERR.
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Figure 4-22: IMRT Trial 1 Gamma Index at 5%/3mm with 96% of pixels passing

Figure 4-22 is an example of the gamma index map for PRESAGE®. The gamma results of the trials
had a standard deviation of ±3% across 3 trials.
4.3.3

Gamma Constraints
Table 4-7 summarizes the average results over three trials for gamma analysis performed

using 3%/3mm, 5%/3mm and 7%/4mm DTA.
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Film
Axial Total

Sagittal Total

Coronal Total

Total Volume

PTV Total

Parotid Total

Cord Total

Normal Tissue
Total

3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm

85±1.6%
93±1.4%
99±0.47%
85±1.4%
90±2.6%
99±0.82%
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

PRESAGE®
Slice
85±2.7%
95±2.6%
98±1.0%
89±2.3%
96±2.0%
100±0.0%
94±1.9%
98±1.1%
99±0.84%
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

PRESAGE® 3D
X
X
X
X
X
X
X
X
X
90±2.2%
96±2.0%
100±0.24%
96±0.93%
100±0.058%
100±0.0%
94±4.7%
99±2.2%
100±0.0%
92±8.1%
98±2.3%
100±0.0%
90±2.4%
96±1.0%
100±0.27%

Table 4-8: Pass rates for 3 levels of gamma constraints

The structures contoured within the PRESAGE® dosimeter were also calculated as they are available
to view once the 3D gamma has been calculated. The more generous constraint of 7%/4mm proved
too lax for evaluation. The results were at or near 100% for all dose measurements. All PRESAGE®
measurements passed the 3%/3mm gamma constraint with a passing rate above 85%. The passing
rates at the 5%/3mm constraint are as shown in Table 4-7 and demonstrated passing rates above
95%. The total volume 3D gamma and the normal tissue 3D gamma (comprised of the total volume
minus all contoured structures) had pixel passing rates of 90% for 3%/3mm, 95% for 5%/3mm and
100% for 7%/4mm. The individual structures had higher pass rates with the lowest result being the
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parotid which showed 92% of pixels passing at 3/3mm. At 5%/3mm the individual structures (PTV,
parotid and cord) were at or above 98% pixels passing.

4.4
4.4.1

Discussion
Open Field Plan
The simplified scenario of the APRL was created as an end-to-end test of phantom

irradiations before performing more complex irradiations. This was the first irradiation utilizing a
TPS to design an irradiation for a PRESAGE® dosimeter in this study and the first data to compare
measured to calculated dose distributions. The TLD data showed the dose delivery in the major
structures was correct and the dose line profiles were also acceptable. The PRESAGE® dose line
profiles showed an increase in dose near the edge of the field close to 5%. These line profiles were
replicating the film profiles and neared the optical edge artifact of the PRESAGE®. It was decided
for future analysis to avoid the optical artifacts that would perturb the dose field.
It was not expected for PRESAGE® to have a passing percentage which was 6 -10 %
different. One reason for this might be the thickness of the film itself. The film thickness is 0.28 mm
(24). The PRESAGE® 2D gamma does take the gamma calculation over the 1 mm thick slice. This
extra dimension can increase the probability of finding a passing pixel within the gamma constraints
as shown by Pulliam et. al. (27).
Another issue discovered was with the film/TLD insert. The current film is thicker than
when the phantom insert was originally designed. Pressure marks on the film from being inserted
and removed from the phantom caused aberrations in dose readout. More care was taken after this
study in cutting film and handling cut-film to minimize any other markings.
The PRESAGE® irradiations show one major condition for which the user should be aware
of: lack of registration. Looking at the dose profiles one can see this. Registration based on fiducials
that were available in x-ray CT and optical CT was not successful. Physical fiducials that could be
viewed in x-ray CT distorted optical-CT imaging. Holes were drilled in the top of a PRESAGE®
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dosimeter to show an air gap in the x-ray CT did not penetrate the top edge artifact of the dosimeter
and could not be identified in the optical readout. Deeper holes were avoided because of concern that
they would interfere with contoured dose volumes. The PRESAGE® registration to the TPS had to be
done qualitatively. This lessened the reproducibility. A registration system that fits within phantoms
(current BBs do not) is needed to increase precision. Another option would be to coordinate the
optical system and CERR to automatically align coordinates using the registration base attached to
PRESAGE® for optical scanning alignment. The current HN phantom was not designed with
depressions for interlocking with the optical alignment base. Overall, the PRESAGE® irradiation and
analysis was within the gamma passing criteria and considered to be of potential use.
4.4.2

IMRT Plan
A clinically relevant IMRT plan was used to irradiate the HN phantom. The film and TLD

results agreed with the TPS IMRT dose calculation showing a correctly irradiated phantom.
Currently, the passing criteria at IROC-Houston for this phantom is 85% pixels passing at 7%/4mm.
The film passes at or above 90% at the stricter criteria of 5%/3mm in both planes. The PRESAGE®
passing results are higher with at least 95% pixels passing at 5%/3mm for a 2D slice from the
PRESAGE® dosimeter. This confirms first part of the hypothesis which states the PRESAGE® 3D
dosimeter will agree with 2D measurements to within ±5%/3mm using a gamma index analysis. The
PRESAGE® dosimeter performed at least as well as the “gold-standard” (for this study) film/TLD
system. The increase in passing pixels was comparable to the results seen with the APRL irradiation.
4.4.3

Gamma Constraints
Gamma constraints have been used for 2D dose measurements since Low et al. introduced

the methodology in 1998 (26). While TG 119 has recommended gamma constraints to be used for
IMRT evaluation it was truly intended for planar dose distribution (49). One study by Pulliam et al
used Monte Carlo calculations and found an increase in passing pixels of up to 2.9% when
comparing 3D and 2D gamma analysis (27). In 2014, this was the first study to closely look into the
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difference in gamma results between planar and volumetric dose distributions. To our knowledge
this study is the first compare planar and volumetric dose measurements for gamma analysis
comparison. Theoretically the third dimension should increase the percentage of passing voxels but it
is unknown by what percentage.
The PRESAGE® dosimeters have consistently shown a higher pass rate compared to the film
data in the previous work using 5%/3mm as a constraint. Two constraints other than 5%/3mm were
chosen for evaluation for this study: the commonly used 3%/3mm criteria and the passing criteria
used by IROC of 7%/4mm. The more generous constraint of 7%/4mm proved too lax for evaluation.
The results were near or at 100% for all dose measurements. The 3%/3mm gamma constraint passed
all volumetric calculations with a passing rate above 87%. The standard deviation of the volumetric
PRESAGE® measurements also increased at the tighter constraint. This might be attributed to a slight
registration misalignment being caught in 3D. A minor rotation in registration might not be detected
in planar analysis but the structure volume misalignment between trials could be magnified.
With the increase in error for volumetric data at the tighter constraint, we decided to continue
working with the 5%/3mm gamma constraint. To account for the deviations over the measured data
and the intention to use this phantom in the IROC phantom program, we chose passing cutoffs of
85% passing pixels at a gamma constraint of 5%/3mm to be considered passing in planar QA while
90% passing pixels at 5%/3mm to be passing volumetric QA. The tighter constraint or a higher
passing percentage (or both) could be used in the future if the standard deviation of PRESAGE®
measurements decreased and more irradiation continue to show reproducibly high passing
percentages.. Improvement in registration could allow the more common 3%/3mm constraint to be
used with this HN phantom and the PRESAGE® dosimeter.
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5 Chapter 5 – Specific Aim 4
5.1

Rationale
The 3D PRESAGE® QA system had been verified against the commissioned film/TLD system

in the previous work of this study. Any new dosimetry system should not be implemented unless it
improves current outcomes. The phantom program at IROC-Houston is well defined and including
PRESAGE® would only be advised if a quantifiable advantage was obtained. The disadvantages of a
longer evaluation time and increase in cost only left the potential benefits of a measured 3D data set
as a benefit that warrants inclusion of the PRESAGE® dosimeter into the phantom program. The aim
of this section was to test the second part of the hypothesis to evaluate whether 3D dataset could
detect errors missed by the current 2D system. And if the volumetric measurement did detect an
error, then how much of a clinical impact would this error have on the treatment delivery? To test
this part of the hypothesis the IMRT plan was modified to introduce different errors into the plan.
These modified plans were then compared to the previously measured dataset using a gamma index
analysis. Secondly, since PRESAGE® yields volumetric data, the NTCP for the parotid gland was
calculated using the measured dose and the calculated dose from each modified treatment plan. A
5% change in NTCP between calculated and measured dose data was considered clinically
significant. This specific aim was completed in 2 parts performed simultaneously:
•

Modify the IMRT plan to create errors and test with 2D and 3D gamma index analysis
and identify situations where a plan passes a 2D quality assurance but fails with the
3D measurement.

•

Calculate the NTCP for the parotid gland over the original measurement and the
modified plans. Identify which plans that only failed the 3D gamma index differed by
5% of the expected NTCP.
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5.2

Methods
The original IMRT plan was modified several times to test whether a 3D measurement would

catch errors where the 2D measurement did not. For cost effectiveness, i.e. minimize the number of
PRESAGE® dosimeters to be manufactured and irradiated, the measured dose distribution from
PRESAGE® irradiated using the original plan was compared to changes made in the TPS. This was
done with confidence because previous work had shown the dosimeter to correctly measure the
calculated dose distribution.
Eight modified plans were used to recalculate the gamma index. Each plan was intended to
showcase a scenario that might pass 2D quality assurance while failing a true 3D measurement. The
first modification was a change in the dose calculation engine. During clinical treatment planning the
Adaptive Convolve engine is used to calculate dose for plans to be reviewed. Because it does a
coarser calculation in regions where TERMA (Total Energy Released in Matter) is relatively
constant, it is quicker than the Collapsed Cone Convolution (CC Convolution) but also less accurate..
Final dose calculation was calculated using CC Convolution. The modified plan “Adaptive
Convolve” illustrated the situation when the final dose calculation was not changed to CC
Convolution.
The second and third modified plans changed the dose grid used for calculation. Chung et al
studied the effect varying the dose calculation grid had on dose in head and neck IMRT (50). The
calculation dose grid used for this study was 3 mm as used in our clinic. The “2 mm Dose Grid” plan
reduced the dose calculation grid down to a size that is not used for HN treatments at the time of the
experiment. The “4 mm Dose Grid” plan increased the dose grid beyond the accepted 3 mm for this
treatment site.
The fourth modification simulated importing the wrong patient plan to the treatment machine.
“Extended Parotid” plan increased the size of the parotid 4 mm in the inferior direction and out of
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the primary beam. This was a small change to increase the volume of a structure used for calculation
in the inverse planning.
The fifth modification involved creating a cold spot near the PTV that was not caught by a
chart check. A structure was placed near the PTV as an avoidance structure to help in the planning
process and was supposed to be removed for the final treatment calculation. In this scenario, the plan
trial with the avoidance in place was accidently used as the final plan and exported for treatment.
The sixth modification titled “Re-Optimization” was an example of a plan being re-optimized
in inverse planning after the plan had been exported for gamma index analysis. This led to a different
optimization (with the exact same constraints) for the actual plan delivery versus the dose calculation
used to compare to the measured dose.
The last three modifications are examples of delivery errors. The first delivery error simulated
a gantry offset. “Angle 122” moved the gantry 2 degrees from the intended beam angle of 120. The
other two delivery errors involved a malfunctioning Multi-Leaf Collimator (MLC). MLC errors are
not always detected during IMRT QA and even less so when testing with doing QA with a composite
plan (51). A 3D measurement might have an increased sensitivity to MLC errors. Two plans were
created to simulate MLC error commonly regarded as a sticky leaf. “Sticky Leaves 1” and “Sticky
Leaves 2” closed 2 to 3 leaves from the MLC for beam angle 80 and 40 respectively.
The NTCP was calculated for all three trials of PRESAGE® irradiations and compared to the
treatment plan’s calculations. The dose in CERR was increased to cover a full treatment and the
NTCP function in CERR and the inputs from Dijkema et al of n=1, TD50 = 40.5 and m=0.36 were
input into the program (48). The dosimeter with the smallest difference between plan and
measurement for NTCP was used to compare to all further plan modifications.
Each modified plan’s dose was imported into CERR and the dose was scaled to cover a full
treatment. The NTCP was calculated for each plan. Gamma index analyses in 2D and 3D were also
performed at a gamma index of 5%/3mm with 85% pixels passing considered passing 2D quality

76
assurance and 90% pixels passing considered passing 3D quality assurance. Plans that passed 2D
quality assurance but failed 3D quality assurance were sorted by the percent change in NTCP. A 5%
change was considered clinically relevant.

5.3

Results
The first step was to determine the best PRESAGE® dosimeter for analysis. Table 5-1 shows

the results of the NTCP change from the original IMRT plan and each trial. Trial 3 had the smallest
change in percent from the original at 0.64% and was used for all gamma analysis and has the
baseline for the change in NTCP with the modified plans. Figure 5-1 shows the GUI used in CERR
to model NTCP for Trial 3.
Dose name
Original IMRT Plan
Trial 1
Measurement
Trial 2
Measurement
Trial 3
Measurement

NTCP
change in
%
%
25.4%
0.00%
29.4%
4.06%
26.7%

1.37%

26.0%

0.64%

Table 5-1: NTCP values from Measured Dose

Figure 5-1: NTCP modeling from CERR for Trial 3 dose measurement
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Each modified treatment plan was imported to CERR and analyzed using a 5%3mm gamma
constraint identified in the previous section. The percentages of passing pixels for each plan are
summarized in Table 5-2. Furthermore the NTCP was modeled for each plan. Table 5-3 summarizes
the NTCP results.
For the change in dose algorithm to Adaptive Convolution from CC Convolution, the 2D
gamma index analysis showed 96% pixels passing for 5%/mm criteria in both the axial and sagittal
planes. The 3D gamma had a lower passing percentage of 91% pixels passing for 5%/3mm criteria.
This plan passed both QA tests. The NTCP over the parotid gland increased by 2.4% from the
original measurement.
The 2 mm dose grid test passed with at least 96% pixels passing in both planes for 2D analysis
using 5%/3mm criteria. The 3D gamma analysis showed 92% of pixels passing using 5%/3mm. The
NTCP increased by 3.84% from the measured probability. The 4 mm dose grid plan passed 2D QA
with at least 90% of pixels passing using 5%/3mm for both planes. The 3D QA failed with 89%
pixels passing at 5%/3mm. The passing cutoff was 90% pixels passing. The NTCP increased 4.85%.
The extended parotid plan passed 2D QA with at least 86% of pixels passing for both planes. The
plan failed 3D QA with only 82% of pixels passing using 5%/3mm criteria. The NTCP decreased
9.23%.
The plan that left a cold spot within the PTV failed QA in both 2D and 3D with the 5%/3mm
gamma criteria. Only 63% of pixels passed in the axial plane and 81% of pixels passed in the sagittal
plane. 66% of pixels passed in the 3D volume. The NTCP increased 2.38%.
The Re-Optimization plan failed 2D QA with only 75% pixels passing the sagittal plane for
5%/3mm criteria. The plan also failed in the 3D QA with 79% pixels passing using 5%/3mm. The
NTCP increased by 5.61%.
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The beam angle plan passed 2D gamma analysis with at least 93% of pixels passing at
5%/3mm in both planes. The 3D gamma analysis showed 93% of pixels passing for 5%/3mm. The
NTCP increased by 0.97%. Both sticky leaves plan 1 and 2 passed QA with 2D gamma constraints
having at least 96% pixels passing for plan 1 and 94% pixels passing for plan 2 at 5%/3mm. The 3D
gamma had a passing rate of 91% and 90% at 5%/3mm for plans 1 and 2 respectively. The NTCP
increased by 4.2% for plan 1 and by 2.99% for plan 2.

Axial
Slice
Sagittal
Slice
3D
Gamma

Adaptive
Convolve

Extended
Parotid

2mm
Dose
Grid

4mm
Dose
grid

ReOptimization

Cold
Spot

Beam
Angle
122

Sticky
Leaves

Sticky
Leaves
2

96%

86%

97%

96%

85%

63%

96%

96%

94%

96%

94%

96%

90%

75%

81%

93%

97%

98%

91%

82%

92%

89%

79%

66%

93%

91%

90%

Table 5-2: 2D and 3D Gamma Results at 5%/3mm

Dose description

Pass 2D?

Pass 3D?

NTCP %

Adaptive Convolve

yes

yes

28.4%

change in
%
2.4%

2mm dose grid

yes

yes

29.8%

3.8%

4 mm dose grid

yes

no

30.8%

4.9%

Extended Parotid
Re-Optimization

yes
no

no
no

16.8%
31.6%

9.2%
5.6%

Cold Spot

no

no

28.4%

2.4%

Beam Angle 122

yes

yes

27.0%

1.0%

Sticky Leaves

yes

yes

30.2%

4.2%

Sticky Leaves 2

yes

yes

29.0%

3.0%

Table 5-3: Gamma Index and NTCP results. Highlighted results passed a 2D evaluation and failed a 3D
evaluation.

Only 2 plans passed a 2D gamma criterion and failed the 3D gamma criterion. Of those two,
only the “extended parotid” plan showed a change in NTCP of 5%. The plan changing the
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calculation dose grid to 4mm from 3mm was close with a NTCP change of 4.9%. There were no
instances where the 3D gamma evaluation passed a plan the 2D evaluation failed.
The second part of the hypothesis stated the PRESAGE® dosimeter will detect dose
distribution discrepancies for complex treatments not detected by 2D planar film measurements that
will result in a 5% difference in NTCP. In fact, of nine experiments, the PRESAGE® dosimeter
detected a discrepancy resulting in more than 5% difference in NTCP that was not detected by 2D
planar measurements. Consequently, while the hypothesis is not conclusively demonstrated, these
results argue that the hypothesis cannot be rejected.

5.4

Discussion
The last section of this study evaluated different treatment scenarios and how a PRESAGE®

volumetric dose measurement affected outcome compared to 2D evaluation. Seven of the modified
plans passed 2D quality assurance at 5%/3mm. This result was surprising as many institutions using
the IROC phantom are unable to pass at a higher pass criterion. This phantom has shown its ability to
catch treatment planning as well has delivery errors. The PRESAGE® dosimeter and film analysis
was shown as comparable in Table 4-7 and we did not expect the PRESAGE® to pass this amount of
modified plans.
Both plans that altered the MLC (Sticky Leaves and Sticky Leaves 2) passed 2D and 3D.
The 3D gamma had a lower pass rate for both plans by at least 4-5%. We expected a 3D gamma to
have an equal or higher pass rate for a truly passing irradiation. The lower pass rate from the 3D
gamma showed the MLC modification does have a greater dose discrepancy over the volume than
can be measured with planar QA suggesting the 3D measurement has an increased sensitivity. The
adaptive convolve plan also had a lower 3D passing rate when compared to the 2D. This dose
algorithm change was another subtle error that showed a greater impact when a full volumetric dose
was studied. If PRESAGE® was brought into a QA system more routinely, this low of a score might
flag further evaluation.
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The plans that failed all quality assurance were the re-optimization plan and the intentional
cold spot plan. Both plans involved inverse planning (instead of a single dose re-calculation without
optimization) and did not change the dose field significantly enough to be detected. These results
were not surprising. To detect a change, a significant number of voxels need to experience dose
adjustments and the Adaptive Convolve and CC Convolution use the same dose algorithm but
calculate on a different grid in parts of the plan.
The two plans that only failed using a 3D gamma analysis were the extended parotid plan and
the 4 mm dose grid. The extended parotid plan was expected to fail as it changed the dose field
outside of the planes used for 2D analysis. With a measured volumetric dose on hand a dose volume
histogram (DVH) was easily created to look at any dose discrepancies in the major structures.

Figure 5-2: Dose Volume Histogram for the Extended Parotid plan and Trial 3 measurement

Figure 5-2 shows the DVH for the extended parotid plan. The modified dose to the cord and the
parotid gland were lower across the volume than the original plan measurement. A true measured
DVH can be made for any measurement taken with the PRESAGE® dosimeter. While impractical to
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look at every parameter of data that PRESAGE® measured it is invaluable to have the information
when troubleshooting a low-scoring or failing irradiation.
The 4mm dose grid plan also failed with the 3D gamma. This dose grid is larger than the 3
mm dose calculation grid typically used at our institution for head and neck patients. Niemierko et al
noted that the larger the dose penumbra, the greater the interpolation errors are for a given grid size
(52). Yan et al recommended no larger than a 2mm dose grid size for HN cases for this same reason
even though 3 mm and 4 mm dose grid sizes were suitable for most cases of IMRT (51). It is
considered for this plan the interpolation errors over volume caused the failure in 3D.
NTCP is a metric that can be used to predict clinical outcome inpatients. This is a volumetric
calculation and easily calculated in CERR with our volumetric dataset. With all of the plan
modifications, only 2 plans had a 5% change in NTCP: Re-Optimization and Extended Parotid. The
Re-Optimization plan failed planar QA and would not have been used for treatment but the Extended
Parotid case only failed using 3D gamma analysis. The NTCP change of 9.2% suggests a change in
clinical outcome could be possible when treating with this modified plan. This showed PRESAGE®
was able to catch an error that could have an impact where the original film/TLD insert did not. The
second plan to only fail when tested with a 3D gamma had a change of NTCP of 4.9%. While not at
the 5% level for the hypothesis of this project this number could still be considered significant to
come clinicians. Further investigation into biological metrics with 3D measured datasets should be
conducted to quantify the impact a true measured 3D dataset could have for a clinic.
With 3D measurements, once a gamma analysis had failed the full volumetric dose
measurement was already in place to further investigate the problem without a re-irradiation. This
can be a time and cost saving technique to identify the cause of the discrepancy. In this case, by
looking at the 3D gamma difference and the DVH a physicist could suggest an institution needs to
confirm they treated with or uploaded the correct treatment plan for analysis prior to suggesting a reirradiation with the same plan. Being able to investigate with the failing dose measurement instead of
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having to re-irradiate and hope to re-create the error can help increase quality control for patientspecific IMRT QA.
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6 Chapter 6 – Conclusion
6.1

Summary
This project was intended to test whether a measured 3D dataset could provide greater value

than the current process that could affect the quality of care of patients in the future. This project was
done using a PRESAGE® dosimeter in an IROC-Houston HN phantom. We hypothesized that
complex dose distributions measured with the PRESAGE® 3D dosimeter will agree with 2D
measurements to within ±5%/3mm using a gamma index analysis. Also, the PRESAGE® dosimeter
would be able to detect dose distribution discrepancies for complex treatments not detected by 2D
planar film measurements that would result in a 5% difference in NTCP.
This project was completed in 4 parts. In the first part an optical-CT system was set up and
verified for use. A standard of practice was created to ensure that data measured would be
independent of the user. A quality assurance program was designed to verify the optical density
measured would be consistent prior to data acquisition. This section created a stable optical-CT
scanning protocol for reproducibility and reliability.
The second part of this study assessed the capability of the PRESAGE® dosimeters for remote
quality assurance. A dose calibration procedure was devised for each bath of dosimeters. The
temporal and thermal stability of a 500g dosimeter was studied. We found in this section remote
dosimetry was feasible. A dosimeter’s thermal and temporal history were important to record and all
irradiations need to be performed at room temperature. It was recommended while using
PRESAGE® as a relative dosimeter, a calibration could be done with cuvettes from the same
dosimeter batch.
The third part of the study used the HN phantom from the IROC-Houston phantom program to
measure dose distributions from a calculated treatment plan. A gamma index analysis was used to
record the percentage of passing pixels for two dosimetry systems: the film/TLD insert credentialed
by IROC-Houston and the PRESAGE® insert. Various gamma constraints were used for analysis to
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attempt to define an appropriate constraint for an acceptable IMRT quality assurance. That data
suggest that volumetric dosimetry may be able to use tighter constraints that 2D analysis, but the
study of site-by-site investigation of that was not in the scope of this research.
The last section of this project tested whether PRESAGE® measurements would be able to
detect errors in dose delivery that 2D measurements did not. Furthermore, we wanted to know if
these plans that only failed using 3D detection would have a change in the NTCP metric. Treatment
plans were modified to create errors. These plans were analyzed using the correctly irradiated
PRESAGE® dataset from the previous section. Two of the treatment plans passed the 2D gamma
index analysis and failed the 3D gamma analysis. One of these plans resulted in a 5% change in
NTCP.

6.2

Conclusion
Using a 3D dosimeter and optical-CT readout brought new challenges. With a goal of using

PRESAGE® in the IROC-Houston phantom project, creating a stable readout procedure was
necessary. Any discrepancies in the measured dataset needed to be due to dose delivery errors and
not from a dosimeter or read-out malfunction. Quality control of the optical-CT scanner and correct
handling of the PRESAGE® dosimeters allowed us to move forward to using the PRESAGE®
dosimeter for phantom irradiations.
From the measured dose distributions we concluded the PRESAGE® dosimeter did agree with
2D measurements to within ±5%/3mm and proved the first half of the hypothesis correct. Various
gamma constraints were investigated to try and define a cutoff for passing a gamma index analysis in
3D. As this work continues, more irradiations using different treatment sites would better define the
appropriate criteria for a volumetric dataset. The NTCP metric was used to predict a change in
patient outcome using 3D dose measurements. One modified treatment plan passed a 2D analysis
and failed the 3D analysis with a 5% change in NTCP showing it is possible for the second half of
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the hypothesis to be correct. This suggested the volumetric dose measurement could have an impact
on clinical outcome.

6.3

Future Works
Volumetric dosimetry is fast changing in these times. Over the course of this project, the

scanner, the code used for analysis and the dosimeter itself underwent upgrades. This project
outlined a successful procedure for scanning and scanner quality assurance. New formulations of
PRESAGE® should undergo the same thermal and temporal studies as shown in this project prior to
being used for any remote dosimetry. Software upgrades must always be validated prior to use.
CERR is an open-source platform that is constantly being changed. Careful consideration is needed
before upgrading any of the code.
The most pressing work to be completed for this system is a registration system for the
dosimeter with a treatment plan. This would reduce analysis errors and decrease the time it takes a
user to measure data. In a full scan and analysis, at this time dose registration with a treatment plan
almost always takes the most amount of time to perform correctly. A registration system would also
allow for phantom setup errors to be detected. By aligning the measured dose with the planned dose
distribution the phantom no longer measures setup error.
This project focused on the HN phantom. More patient sites should be similarly evaluated.
This would test the different shapes that PRESAGE® could be successfully used in optical-CT and
increase the overall dataset for gamma analysis working towards an improved recommendation for
gamma analysis constraints with measured volumetric data.
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7 Appendix
The individual trials are listed below for each dosimeter.
TLD Location

Measured
Dose (cGy)

Predicted
Dose (cGy)

Measured/Predicted
Dose

PTV Sup Post

531

528

1.00

PTV Inf Post

520

519

1.00

PTV Sup Ant

520

526

0.99

PTV Inf Ant

529

521

1.02

Cord Superior

492

486

1.01

Cord Inferior

484

479

1.01

Parotid Superior

500

495

1.01

Parotid Inferior

490

490

1.00

Table 7-1: TLD Results for Trial 1 from APRL Plan

TLD Location

Measured
Dose (cGy)

Predicted
Dose (cGy)

Measured/Predicted
Dose

PTV Sup Post

533

528

1.01

PTV Inf Post

535

519

1.03

PTV Sup Ant

536

526

1.02

PTV Inf Ant

533

521

1.02

Cord Superior

498

486

1.03

Cord Inferior

497

479

1.04

Parotid Superior

496

495

1.00

Parotid Inferior

500

490

1.02

Table 7-2: TLD Results for Trial 2 from APRL Plan
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TLD Location

Measured
Dose (cGy)

Predicted
Dose (cGy)

Measured/Predicted
Dose

PTV Sup Post

526

528

0.99

PTV Inf Post

533

519

1.03

PTV Sup Ant

533

526

1.01

PTV Inf Ant

536

521

1.03

Cord Superior

497

486

1.02

Cord Inferior

494

479

1.03

Parotid Superior

496

495

1.00

Parotid Inferior

499

490

1.02

Table 7-3: TLD Results for Trial 2 from APRL Plan

Area of
Interest
Axial
Sagittal
Coronal
Volume

Film

PRESAGE®

87%
92%
X
X

98%
100%
100%
X

PRESAGE®
3D - 5mm
X
X
X
94%

Table 7-4: 2D Gamma Results at 5%/3mm for Trial 1 from APRL Plan

Area of
Interest
Axial
Sagittal
Coronal
Volume

Film

PRESAGE®

92%
94%
X
X

99%
98%
99%
X

PRESAGE®
3D - 5mm
X
X
X
95%

Table 7-5: 2D Gamma Results at 5%/3mm for Trial 2 from APRL Plan
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Area of
Interest
Axial
Sagittal
Coronal
Volume

Film

PRESAGE®

86%
94%
X
X

96%
99%
98%
X

PRESAGE®
3D - 5mm
X
X
X
94%

Table 7-6: 2D Gamma Results at 5%/3mm for Trial 3 from APRL Plan

TLD Location

Measured
Dose (cGy)

Predicted
Dose (cGy)

Measured/Predicted
Dose

PTV Sup Post

674

686

0.98

PTV Inf Post

701

688

1.02

PTV Sup Ant

683

688

0.99

PTV Inf Ant

683

690

0.99

Cord Superior

313

318

0.98

Cord Inferior

309

300

1.03

Parotid Superior

304

308

0.99

Parotid Inferior

321

333

0.96

Table 7-7: TLD Results for Trial 1 from IMRT Plan

TLD Location

Measured
Dose (cGy)

Predicted
Dose (cGy)

Measured/Predicted
Dose

PTV Sup Post

665

686

0.97

PTV Inf Post

679

688

0.99

PTV Sup Ant

675

688

0.98

PTV Inf Ant

681

690

0.99

Cord Superior

314

318

0.99

Cord Inferior

295

300

0.98

Parotid Superior

306

308

0.99

Parotid Inferior

338

333

1.02

Table 7-8: TLD Results for Trial 2 from IMRT Plan
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TLD Location

Measured
Dose (cGy)

Predicted
Dose (cGy)

Measured/Predicted
Dose

PTV Sup Post

665

686

0.97

PTV Inf Post

685

688

1.00

PTV Sup Ant

688

688

1.00

PTV Inf Ant

693

690

1.01

Cord Superior

317

318

1.00

Cord Inferior

297

300

0.99

Parotid Superior

297

308

0.97

Parotid Inferior

324

333

0.97

Table 7-9: TLD Results for Trial 3 from IMRT Plan
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Film
Axial Total

Sagittal Total

Coronal Total

Total Volume

PTV Total

Parotid Total

Cord Total

Normal Tissue
Total

3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm

87%
95%
99%
87%
94%
100%
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

PRESAGE®
Slice
86%
96%
99%
91%
98%
100%
92%
99%
100%
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

PRESAGE® 3D
X
X
X
X
X
X
X
X
X
92%
98%
100%
95%
100%
100%
90%
100%
100%
83%
99%
100%
93%
97%
100%

Table 7-10: Percentage of passing pixels for various Gamma Index Restraints for Trial 1 from IMRT
Plan
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Film
Axial Total

Sagittal Total

Coronal Total

Total Volume

PTV Total

Parotid Total

Cord Total

Normal Tissue
Total

3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm

83%
92%
98%
84%
88%
99%
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

PRESAGE®
Slice
81%
92%
97%
91%
96%
100%
97%
97%
99%
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

PRESAGE®
3D
X
X
X
X
X
X
X
X
X
88%
94%
99%
96%
100%
100%
94%
96%
100%
93%
95%
100%
89%
95%
99%

Table 7-11: Percentage of passing pixels for various Gamma Index Restraints for Trial 2 from IMRT
Plan
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Film
Axial Total

Sagittal Total

Coronal Total

Total Volume

PTV Total

Parotid Total

Cord Total

Normal Tissue
Total

3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm
3%/3mm
5%/3mm
7%/4mm

85%
92%
99%
84%
89%
98%
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

PRESAGE®
Slice
88%
98%
98%
86%
93%
100%
94%
99%
98%
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

PRESAGE®
3D
X
X
X
X
X
X
X
X
X
89%
97%
100%
97%
100%
100%
100%
100%
100%
99%
100%
100%
88%
96%
100%

Table 7-12: Percentage of passing pixels for various Gamma Index Restraints for Trial 3 from IMRT
Plan
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The following code was written to complete analysis in MATLAB. The first section of code
exports the dose-line profile from the CERR GUI to Excel for further evaluation.
function doseProfileExport(command)
%GC: xlswrite failed on some occasions and was replaced with
%cell2csv, which exports as .csv instead of .xlsm.
%RLG 02/2012
%This is a callback file for an Export button in the CERR file
%doseProfileFigure. The mfile can be found in the PlanAnalysis Folder.
%Once a single treatment plan and a single Presage dose is clicked in the
%viewer, press the export button to save to Excel. This is based on
%plotpresage.m
global planC
global stateS
indexS = planC{end}(36);
initialDoseV = [];
initialScanV = [];
hFig=findobj('tag','CERR_DoseLineProfile');
ud=get(hFig,'userdata');
udS=get(ud.slideraxis,'userdata');
xDataL=get(udS.xL,'xData');
x1=xDataL(1);
xDataR=get(udS.xR,'xData');
x2=xDataR(1);
nSamples=stateS.optS.numDoseProfileSamples;
ptsDel=1:nSamples;
ptsL=nSamples/0.95*(x1-0.025);
ptsR=nSamples/0.95*(x2-0.025);
ptsDel=unique([1:floor(ptsL) ceil(ptsR+1e-6):nSamples]);
%get UD stored variables
doseUI=ud.doseUI;
scanUI=ud.scanUI;
nDoses=ud.nDoses;
nScans=ud.nScans;
startPt=ud.startPt;
endPt=ud.endPt;
drawDoses=[];
for i=1:nDoses
drawDoses(i)=get(doseUI(i),'value');
end
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drawScans=[];
for i=1:nScans
drawScans(i)=get(scanUI(i),'value');
end
drawDoses=find(drawDoses);
drawScans=find(drawScans);
%Get xyz coord. of samples and distance from first pt
xV=linspace(startPt(1),endPt(1),nSamples);
yV=linspace(startPt(2),endPt(2),nSamples);
zV=linspace(startPt(3),endPt(3),nSamples);
distV=sqrt(sepsq(startPt', [xV;yV;zV]));
for i=1:length(drawDoses)
doseNum=drawDoses(i);
transM=getTransM('dose',doseNum,planC);
if ~isempty(transM)
[xV1,yV1,zV1]=applyTransM(inv(transM),xV,yV,zV);
else
xV1=xV; yV1=yV; zV1=zV;
end
dV{i}=getDoseAt(doseNum,xV1,yV1,zV1,planC);
dV{i}(ptsDel)=NaN;
end
[fileName, pathName]=uiputfile('*.csv','Export Profile');
% GC: extension changed to .csv instead of .xlsm
%outString{1}='Distance';
%outData=outString;
%Edit next line is want to export more than one presage profile. Contibue
%to add dV{i} until complete. Also edit outData
allData=num2cell([distV; dV{1}; dV{2}]');
outData = {'Distance', 'Plan', 'Presage'};
%outData = {'Distance', 'Divided', 'Post', 'Pre'};
plotOutput=cat(1,outData,allData);
cell2csv(fullfile(pathName,fileName),plotOutput);
% GC: xlswrite replaced with cell2csv
end

The second piece of code allows for the 2D gamma to be cropped from the full plane to only
the area of interest. After CERR calculates the plane of data, the user then can reduce the area of
interest to within the dosimeter.
function cropGamma
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%crops 2D gamma provided by CERR to size of the dosimeter. A mask is
%created outside of the dosimeter area and set to equal unity and therefore
%not counted in the pass/fail criteria. This is a call back in the
%CERRGammafnc.m that is found in PlanAnalysis\gamma in the CERR folders
% RLG 06/2012
global stateS
gamma = stateS.gamma.gamma2D;
figure('numbertitle','off','name','Select Dosimeter Area'); imagesc(gamma);
h=impoly;
BW = createMask(h);
mask = gamma;
mask(~BW)=1;
pass = length(find(mask<1));
fail = length(find(mask>1));
total = pass + fail;
xx=[pass fail];
passPer = Roundoff((pass/total)*100,2);
failPer = Roundoff((fail/total)*100,2);
Fig = figure('Name','Cropped Gamma','NumberTitle','off','position',[10 , 10 , 1000 , 600],...
'resize','off','tag','gamma2dfig');
Axis = axes('parent',Fig,'units', 'pixels','position',[10 ,10 , 580 , 580],'color', [0 0 0], 'xTickLabel', [],...
'yTickLabel', [],'xTick', [],'yTick', []);
clrBarAxis = axes('parent',Fig,'units', 'pixels','position',[595 ,10 , 15 , 550],'color', [0 0 0], 'xTickLabel',
[],...
'yTickLabel', [],'xTick', [],'yTick', []);
imagesc(mask,'parent',Axis), colorbar(clrBarAxis,'peer',Axis);
set(Axis,'xTickLabel', [],'yTickLabel', [],'xTick', [],'yTick', []);
pieAxis = axes('parent',Fig,'units', 'pixels','position',[760 ,350 , 180 , 180],'color', [0 0 0], 'xTickLabel',
[],...
'yTickLabel', [],'xTick', [],'yTick', []);
pie(xx,[0 1],{['Pass=' num2str(passPer) '%'],['Fail=' num2str(failPer) '%']});
uicontrol(Fig,'Style','text','position',[700, 160, 200, 20],'String',...
['DTA =' num2str(stateS.gamma.DTA *10) ' mm'],'fontsize',10)
uicontrol(Fig,'Style','text','position',[700, 130, 200, 20],'String',...
['Dose Diff = ' num2str(stateS.gamma.doseDiff) ' %'],'fontsize',10)
uicontrol(Fig,'Style','text','position',[700, 100, 200, 20],'String',...
['Max Base Dose = ' num2str(stateS.gamma.refDoseScale) ' GY'],'fontsize',10)
uicontrol(Fig,'Style','text','position',[700, 70, 200, 20],'String',...
['Pass = ' num2str(passPer) '%' ' ' 'Fail = ' num2str(failPer) '%'],'fontsize',10)
uicontrol(Fig,'Style','text','position',[700, 30, 200, 20],'String','Pass < 1 Fail > 1','fontsize',10)
uicontrol(Fig,'Style','text','position',[780, 5, 150, 10],'String','Gamma above 2 is snapped to
2','fontsize',7,...
'fontweight','bold','ForegroundColor',[1 0 0])
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end
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